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ABSTRACT 
 
 
 Amplification of hematopoietic stem cells (HSCs) from human cord blood has 
applications for a variety of cell therapy protocols.  The purpose of this thesis (performed 
in collaboration with ViaCell, Inc.) was to analyze differential gene expression 
(especially related to cytokines) during the process of human HSC amplification in vitro. 
When applied to markers previously shown to be specific for HSC’s and/or progenitor 
cells, the analysis validates ViaCell’s cellular product.  Total cellular RNA was isolated 
from cord blood samples at various stages of amplification and used to synthesize cDNAs 
as probes for hybridization arrays.  mRNA candidates increased in cell populations 
enriched for stem cells were first identified using hybridization arrays, then confirmed by 
RT-PCR.  Restriction mapping confirmed RT-PCR amplicons.  The results identified 
several developmentally interesting cytokines (CD117, Jagged-2, Manic Fringe, and 
Notch) upregulated in stem cell enriched fractions.  Analysis of one candidate previously 
shown to be a marker for HSCs and progenitors, CD117, was extended using Western 
blots to show a CD117-related protein upregulation.  The observed upregulations did not 
contain many inflammatory cytokines, which could hinder survival of HSC grafts.  The 
future hope for the non-CD117 candidates is as potential growth modifiers for stem cell 
samples isolated by clonogenic amplification.  
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BACKGROUND 
 
 
 
What Are Stem Cells? 
 
  In 1909, Alexander Maximow was the first person to suggest that there was a 
hematopoietic stem cell (HSC) with the morphological appearance of a “lymphocyte” 
capable of migrating through the blood to microecological niches that would allow them 
to proliferate and differentiate along lineage specific pathways (Fliedner, 1998). However 
these HSC’s were not actually identified until 1984 from human bone marrow.  Curt 
Civin, professor of Oncology and Pediatrics at John Hopkins University, developed in 
1984 (Civin and Loken, 1987) the CD34 monoclonal antibody that makes it possible to 
identify, isolate, and collect hematopoietic stem cells (Rienzi, 1999).  Prior to Civin’s 
discovery in 1984, doctors harvested patient’s bone marrow before chemotherapy and 
then returned it to the patient’s body.  Unfortunately, this method easily spread the cancer 
to the rest of the body since the transplanted bone marrow still contained cancerous cells. 
However, using the CD34 antibody to bind stem cells, followed by FACS to remove 
these “stained” cells, a patient’s noncancerous stem cells can be harvested from the 
marrow and introduced back into the patient, in turn renewing the body’s blood and 
immune system (Rienzi, 1999).  
Stem cells are characterized by their capacity for extensive proliferation and 
differentiation (de Wynter et al., 1998), as they have the ability to divide for indefinite 
periods in culture and can give rise to specialized cells (NIH, 2000).    
As stem cells proliferate, they give rise to lineage-committed cells with 
more proliferative potential, which in turn mature to functional end cells 
(de Wynter et al., 1998).   
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Figure 1 shows the most important scientific breakthrough of the 20th century, the 
discovery of the stem cell. 
 
 
 
 
 
 
 
 
Figure 1. A microscopic look at a hematopoietic stem cell  
(McLaren, 2001).   
 
 
 
Levels of Stem Cell Potency 
 
During normal human development, when a sperm fertilizes an egg, it creates a 
new cell that has the potential to form an entire human being, as seen in Figure 2.  This 
fertilized egg is totipotent, which means that it has the capacity to specialize into 
extraembryonic membranes and tissues, the embryo, and all postembryonic tissues and 
organs (NIH, 2000).   
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 Figure 2.  Summary of stem cell development into a human being. 
(NIH, 2000) This diagram displays the development of totipotent cells into an adult human being. 
The fertilized egg is itself totipotent and will eventually give rise to specific cells and tissues. 
        
About four days after fertilization, these totipotent cells begin to form a hollow sphere of 
cells called a blastocyst (NIH, 2000).  This blastocyst has an outer layer of cells and an 
inner cell mass (middle diagram, figure 2).  These inner cell mass cells are pluripotent, 
which means they are capable of giving rise to most tissues of an organism (NIH, 2000) 
but they do not have the ability to develop into a fetus.  Pluripotent cells undergo further 
specialization into multipotent stem cells that are committed to give rise to cells with a 
particular function (NIH, 2000). The more specialized multipotent stem cells can be 
found in adult tissue (NIH, 2000).  These stem cells (including HSCs as an example) are 
needed to replenish older cells that are continuously dying off, such as skin and blood 
cells. Figure 3 shows the levels of differentiation competence of various stem cells. 
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 Figure 3. Levels of  stem cell differentiation.  
(NIH, 2000) This diagram displays the various competence levels of 
totipotent cells, pluripotent cells, and multipotent stem cells.  
  
 
 
Stem Cells and Hematopoiesis 
One example of a multipotent stem cell is the hematopoietic stem cell (HSC).  
HSCs are the source for red blood cells, white blood cells, and platelets (t. Breeders, 
2000). HSCs are usually found in bone marrow, umbilical cord blood, and in the 
peripheral blood if they are stimulated to be released from the bone marrow by factors 
such as granulocyte colony-stimulating factor (G-CSF) (t. Breeders, 2000).   However, 
the HSC can differentiate into myeloid stem cells and lymphoid stem cells (Brown, 
1996), which define two basic pathways (Figure 4). 
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 Figure 4. Hematopoiesis proliferation and differentiation pathways. 
This diagram shows the differentiation of a hematopoietic stem cell by 
two major pathways, lymphoid and myeloid (Capra et al., 1999). 
 
 
 
Myeloid stem cells further differentiate into leukocytes, erythrocytes, and 
megakaryocytes.   The erythroid line gives rise to red blood cells (Sullivan, 2000).  The 
megakaryocytic line provides blood platelets, which are the primary defense against 
hemorrhage, and maintaining and repairing the endothelium (Sullivan, 2000).  The 
phagocytic line divides into two subdivisions, the monocytic pathway (which gives rise 
to blood monocytes) and the granulocytic pathway (which gives rise to neutrophils, 
eosinophils, and basophils) (Sullivan, 2000). Lymphoid progenitor cells give rise to T- 
and B-lymphocytes (Capra et al., 1999).    Many cytokines are produced by the T-
lymphocyte cell lineage (Babakhanian, 1995).   
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The T- and B- lymphocytes are distinguished by their sites of 
differentiation- T cells in the thymus and B cells in the bone marrow – and 
by their antigen receptors as seen in Figure 5.  B-lymphocytes differentiate 
on activation into antibody-secreting plasma cells, and T-lymphocytes 
differentiate into cells that can kill infected cells or activate other cells of 
the immune system (Capra et al., 1999). 
 
 
                                Figure 5.  Lymphocytes and Immunity.   
Lymphocytes are made from bone-marrow stem cells, and then 
processed -- B cells in the bone marrow and T cells in the thymus 
(Hurlburt, 1999).   
 
   
How are Stem Cells Identified?  
The CD34 antigen is a defining cell surface marker of hematopoietic 
stem/progenitor cells (HSPC).  It is expressed in virtually all human hematopoietic 
progenitors and their precursors, including most (if not all) mammalian stem cells (Opie 
et al., 1998).  It has been suggested that this cell surface molecule functions as a regulator 
of hematopoietic cell adhesion to stromal cells of the hematopoietic environment (Healy 
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et al., 1995).  The frequency of CD34+ cells in adult bone marrow has been estimated to 
be 1%-3% of all nucleated cells (Civin and Loken, 1987), and 1% in umbilical cord 
blood (UCB) (Kinniburgh and Russell, 1993). 
The vast majority of UCB CD34+ cells coexpress FLT3, the receptor for the 
early-acting cytokine FLT3-ligand (FL).  However, HSPC lack the expression of both 
HLA-DR and CD38 antigens.  This differs from adult bone marrow, where the majority 
of CD34+ cells express both HLA-DR and CD38 antigens.  The frequency of 
CD34+HLA-DR- and CD34+CD38- cells in UCB are higher than in adult bone marrow, 
suggesting that UCB possesses a higher proportion of immature HPC than human bone 
marrow.  Other antigens also found on the UCB 34+ cells are lymphoid- and myeloid- 
associated antigens, CD13, CD58, and CD44.  Figure 6 displays the steps of t-cell 
development and the key antigens involved in the process (Piascik, 2001). 
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 Figure 6. T-cell development and the key antigens involved. 
 
 
From Where Can Hematopoietic Stem Cells Be Isolated? 
 
 Hematopoietic stem cells can directly be obtained from the bone marrow of a 
patient using a general anesthetic.  Indirectly, stem cells can be increased in the marrow 
(and spill over into the peripheral blood) through various treatments, including the use of 
growth factors (CancerBACUP, 1999).    
Since 1989, umbilical cord blood has proven to be a rich source of hematopoietic 
stem/progenitor cells (Broxmeyer et al., 1989) as an alternative source to bone marrow 
(Kim et al., 1999).   It was found that the frequency of progenitors in UCB equals or 
exceeds that of marrow, and greatly surpasses that of adult blood (Broxmeyer et al., 
1989).  Their work also included examining the prospect of storing the UCB for future 
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research or medical use.  Their results suggested that the UCB from a single donor could 
serve as a good source of autologous or major histocompatibility complex-matched 
allogenic transplantable hematopoietic repopulating cells (Broxmeyer et al., 1989). 
HSCs can be isolated from umbilical cord blood after the birth of a newborn baby.  
The blood is collected, treated, cultured, and counted for use in the laboratory or for 
cryopreservation (Rubinstein et al., 1995).   Knudtzon’s experiments (1974) were the first 
to demonstrate the presence of UCB stem cells.  He found that when human UCB and 
peripheral blood cells are cultured, increased concentrations of colony-forming cells are 
seen in the UCB cultures (Knudtzon, 1974).  The presence of colony-forming cells in 
culture are a good indication that stem cells are present in the original cell population that 
can divide and proliferate in culture.  He also demonstrated the presence of relatively 
immature hematopoietic progenitor cells in human cord blood (Knudtzon, 1974).  
However, it was not until 1989 that UCSCs were used in clinical settings (Mayani and 
Lansdorp, 1998).  That same year, Gluckman et al. (1989) reported the first 
hematopoietic cell transplant in which umbilical cord blood was used instead of bone 
marrow. These scientists were also instrumental in work pertaining to cryopreservaton of 
UCB cells for later use in transplantation from both genetically related and unrelated 
patients (Gluckman et al., 1993).  Survival following cryopreservation of UCB cells was 
found after they assessed the hematopoietic reconstitution in a boy with Fanconi’s 
anemia who received cryopreserved UCB from his sister (Gluckman et al., 1989).  
Mayani and Lansdorp (1998) cultured individual UCB samples supplemented with 
different cytokine combinations and found that cytokines play a permissive role in 
hematopoietic cell commitment.   
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What is Cellular Medicine? 
 
 Stem cells can be used to reconstitute healthy cells and tissues needed for 
medicinal purposes through a concept called cellular medicine.  The aim of this type of 
therapy is to replace, repair or enhance the important biological functions of tissues and 
cells that have been damaged by cancer, trauma, etc (Gage, 1998).  By isolating the 
multipotent stem cells of different organs, transplantation can be performed to a target 
organ to induce healthy function again (Gage, 1998).  Several cell sources are outlined in 
Table 1. 
Cell Source Advantages Disadvantages Solution 
Autologous 
(same patient) 
Immunologically privileged; 
No ethical issues 
Limited supply; 
Time constraints for donor 
and host 
Cryopreserve; 
Amplify in vitro 
Allogeneic 
(same species) 
Greater supply; 
Fewer time constraints on donor 
Cellular immunity; 
Ethical issues: fetal tissues 
Immunosuppress; 
Encapsulate 
Xenograft 
(different 
species) 
Greater supply; 
No time constraints on donor 
Cellular and humoral 
immunity; 
Possible transfer of new 
virus across species 
Immunosuppress; 
Encapsulate; 
Genetically mask 
immunity 
Cell line 
(immortalized or 
tumorigenic) 
Infinite supply; 
No time constraints for donor or 
host; 
Safety test and standardization 
simplified 
Cellular and humoral 
immunity; 
Tumorigenicity and 
neoplasia 
Immunosuppress; 
Encapsulate; 
Genetically mask 
immunity 
Table 1.  Cell source considerations (Gage, 1998).  The table outlines 
the advantages and disadvantages of individual cell sources from which 
multipotent stem cells can be isolated.  
 
 
This stem cell method of transplantation is needed because many diseases result from the 
disruption of cellular function or destruction of tissues of the body (NIH, 2000).  
Currently, organ and tissue transplantation is performed to replace damaged parts of the 
body (for example, the liver, heart, etc.), but the need is much greater than the supply.   
Hematopoietic stem cell transplantation is effective as a treatment for 
selected high-risk patients with hematological malignancies or solid 
tumors treated with high-dose chemotherapy.  Over the past decade, 
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several advances have been made in the collection and manipulation of 
hematopoietic progenitor cells for transplantation (Gage, 1998). 
 
Figure 7 demonstrates the promising stem cell technology that will eventually affect all 
areas of medicine. 
 
Figure 7.  The promise of stem cell research.  
(NIH, 2000) This figure displays the possible uses of stem cells as 
cellular medicine. 
 
 
HSCs are destroyed during cancer therapy.  This destruction represents a major 
source of cancer treatment morbidity and mortality (t. Breeders, 2000).  Therefore, the 
replacement of HSCs is crucial after an individual has undergone radiation or 
chemotherapy.  In stem cell replacement therapy, HSCs are isolated from the patient’s 
own bone marrow or peripheral blood prior to chemotherapy, from a histocompatible 
individual, or from blood taken from an umbilical cord at birth (t. Breeders, 2000).   
These HSCs are amplified then injected back into the patient.   
The principal limitations of stem cell replacement therapy using HSCs isolated 
from the bone marrow are histocompatibility differences, and cell numbers.  It is 
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important for the number of HSCs transplanted to be sufficient to provide a good source 
of blood cells for the patient, and to minimize the time to repopulate the patient’s 
depleted bone marrow.   
The first allogeneic UCB transplant was performed in 1988 on a patient with 
Fanconi’s anemia (Gluckman et al., 1989).   Today the patient is doing well, with full cell 
reconstitution.  In this historical case, the UCB was collected at birth, cryopreserved, and 
transplanted after thawing, without losing its repopulating ability (Gluckman et al., 
1989).  In 1997, Broxmeyer and Cooper determined that UCB cells cryopreserved for up 
to 10 years have a high efficiency recovery of immature and mature progenitors 
(Broxmeyer and Cooper, 1997).  To date, hundreds of UCB transplants have been 
performed, and the data was reported to the Eurocord and Netcord Registry.  Data has 
been obtained from 527 UCB transplants at 121 transplant centers in 29 countries 
(Gluckman, 2000).  The results from these clinical analyses were evaluated from related 
donors in 138 cases, and unrelated in 399 cases, which ultimately showed that there is a 
definite promise in UCB transplantation. It is important to obtain 3x107-nucleated cells 
per kilogram for a successful transplantation (Gluckman, 2000).  
The success and advantages of using UCSCs for transplantation include the ease 
of procurement, no risk to donors, larger donor pool, less risk of transmitting infection or 
viral transmission, prompt availability of cryopreserved samples, and low incidence of 
complications due to graft-vs-host disease (GVHD) (Gluckman, 2000).  These 
advantages make stem UCSC replacement therapy a promising procedure in the future of 
medicine. 
 12 
Thus far, multipotent stem cells have not been found for all adult tissues present 
in the body and are very rare.  Tissues that have identified stem cells display only minute 
quantities within the tissue, which makes it difficult to isolate and purify the stem cells.  
Recently, a population of neural stem cells (NSCs) was found to be present in the adult 
mammalian central nervous system (Rietze, 2001).  Rietze and colleagues isolated the 
NSC, but its precise identity, location, and potential still remain unclear (Rietze, 2001).  
This limits usage of these cells in therapeutic cases.  Since stem cells have a unique 
reconstituting ability, they are also an important target for genetic-based therapies for the 
treatment of hematopoietic disorders (Rosu-Myles et al., 2000). 
 
Cytokines and Their Effect on Inflammation 
 
The term cytokine is used as a generic name for proteins released by cells that 
affect the behavior of other cells.  These proteins serve as a means of communication 
between cells to modify the functional activities of individual cells and tissues (Capra et 
al., 1999).  Cytokines attach to receptors on the outside of cells causing the target cell to 
produce a certain reaction, depending on the cell and the cytokine (Babakhanian, 1995).  
Table 2 displays a list of all known cytokines found to date and their functions.   
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Family Cytokine Actions 
Hematopoietins  Epo Stimulates erythroid progenitors 
  IL-2 T-cell proliferation 
  IL-3 Synergistic action in early hematopoiesis 
  IL-4 B-cell activation, IgE switch, supresses TH1 cells 
  IL-5 Eosinophil growth, differentiation 
  IL-6 
T- and B-cell growth and differentiation, acute phase protein production, 
fever 
  IL-7 Growth of pre-B cells and pre-T cells 
  IL-9 Mast cell enhancing activity 
  IL-11 Synergistic action with IL-3 and IL-4 in hematopoiesis 
  IL-13 
B-cell growth and differentiation, inhibits macrophage inflammatory 
cytokine production and TH1 cells 
  G-CSF Stimulates neutrophil development and differentiation 
  IL-15 IL-2-like, stimulates growth of intestinal epithelium, T cells, and NK cells 
  GM-CSF Stimulates growth and differentiation of myelomononocytic lineage 
  OSM Stimulates Kaposis's sarcoma cells, inhibits melanoma growth 
 LIF Maintains embryonic stem cells, like IL-6, IL-11, OSM 
  SCF Mast/stem cell growth factor 
Interferons IFN-gamma 
Macrophage activation, increased expression of MHC molecules and 
antigen processing components, Ig class switching 
  IFN-alpha Anti-viral, increased MHC class I expression 
  IFN-beta Anti-viral, increased MHC class I expression 
Immunoglobulin 
superfamily B7.1 Co-stimulation of T-cell responses 
  B7.2 Co-stimulation of T-cell responses 
TNF family TNF-alpha Local inflammation, endothelial activation 
  TNF-beta Killing, endothelial activation 
  LT-beta Lymph node development 
  CD40 ligand B-cell activation, class switching 
  Fas ligand Apoptosis, Ca2+-independent cytotoxicity 
  CD27 ligand Stimulates T cell proliferation 
  CD30 ligand Stimulates T and B cell proliferation 
  4-1BBL Co-stimulates T and B cells 
Unassigned TGF-beta Inhibits cell growth, anti-inflammatory 
  IL-1alpha Fever, T-cell activation, macrophage activation 
  IL-1beta Fever, T-cell activation, macrophage activation 
  IL-1 RA 
Binds to but doesn't trigger IL-1 receptor, acts as a natural antagonist of 
IL-1 functions 
  IL-10 Potent suppressant of macrophage functions 
  IL-12 Activates NK cells, induces CD4 T-cell differentiation to TH1-like cells 
  MIF Inhibits macrophage migration, stimulates macrophage 
  IL-16 
Chemoattractant for CD4 T cells, monocytes and eosinophils, anti-
apoptotic for IL-2-stimulated T cells 
  IL-17 Induce cytokine production by epithelia, endothelia, and fibroblasts 
  IL-18 
Induces IFN-gamma production by T cells and NK cells, favors TH1 
induction 
Table 2. Cytokines.  A list of  currently known cytokines and their 
functions (Capra et al., 1999). 
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By interacting through a series of cascades, many cytokines induce other 
cytokines to be secreted (Giasuddin et al., 1997).  Whether a cytokine’s effect is local or 
more distant is likely to reflect the amounts released, the degree to which this release is 
focused on the target cell, and the stability of the cytokine in vivo (Capra et al., 1999). 
Cytokines have powerful effects on hematopoietic stem cells.  For example, cytokines 
such as Interleukin 4 (IL-4) and IL-5 are responsible for the differentiation of individual 
HSCs into other cell types, such as lymphocytes, platelets, neutrophils and macrophages 
(Brown, 1996).  Other factors that control the migration, proliferation and differentiation 
of stem cells are also induced by cytokines (Rosu-Myles et al., 2000). The ability of 
hematopoietic progenitor cells to expand in vitro depends on the kind of cytokines 
present (Mayani and Lansdorp, 1998).  Several cytokines have been linked to the 
proliferation of umbilical cord blood-derived cells, but the best stem cell amplification 
results have been obtained when cytokines are used in combinations that include early-
acting factors, such as stem cell factor (SCF), FLT-3 ligand (FL), and thrombopoietin 
(TPO) (Mayani and Lansdorp, 1998). 
 
What is Expansion Technology? 
The successful proliferation and expansion of a HSC depends on whether the cell 
is already committed to a specific lineage of differentiation, and if so, the specific 
hematopoietic lineage to which it belongs and its stage of maturation (Mayani and 
Lansdorp, 1998).  In order for the cell to exhibit the potential it needs for expansion, it 
needs specific factors that would normally make up the microenvironment in which the 
cell develops.  HSC proliferation and expansion in vitro depends on variables that include 
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non-HSC cell types, cytokines that form the microenvironment, the type of culture 
medium, medium change schedule, temperature, presence or absence or serum, etc.   
Expansion technologies include using CD34 enrichment, which leads to a 
significant increase in the expansion of CD34+ cells compared with unmanipulated 
human UCB cells (Kohler et al., 1999).  This type of enrichment displays optimum 
results when a combination of SCF, FLT-3L (at 300 ng/ml) and IL-3 (at 50 ng/ml) is 
included (Kohler, 1999).  Hunnestad et al. (1999) found that adding Thrombopoietin 
(TPO), an established powerful stimulant of megakaryocyte differentiation and platelet 
production both in vivo and in vitro, to combinations of other factors causes a significant 
increase in CD34+ cells cultured for 14 days (Hunnestad et al., 1999).  
          Gilmore and colleagues at the Western Pennsylvania Cancer Institute, found that 
stimulating the UCB cells, ex vivo, with a combination of two growth factors, flt-3 ligand 
(FL) and thrombopoietin/c-mpl ligand (TPO/ML) caused the UCB-HSC cells to expand 
(Gilmore et al., 2000).  Brugger et al. cultured cells for 12-14 days in a combination of 
SCF, IL-1, IL-3, IL-6, and EPO, which produced a population of cells with the ability to 
restore neutrophils and platelets rapidly in patients treated with high-dose chemotherapy 
(Brugger, 2000).   
The optimal choice of factors in the expansion of UCB-HSCs has not yet been 
determined, but the findings of these and other researchers are proving to be important to 
the final goal of obtaining the amount of cells needed for successful transplantations. The 
work that already has been done has lead hematologists to explore ex vivo expansion for 
clinical use.  
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ViaCell’s Research Interests 
 
ViaCell, Inc. is a new cellular medicine company merged from two companies: 
Viacord, Inc. in Boston, Massachusetts, and t. Breeders, Inc. in Worcester, 
Massachusetts.  Viacord specializes in storing cord blood stem cells from the umbilical 
cords of newborns for future use within that family.  t. Breeders is a biotechnology 
company with proprietary technology for expanding UCSCs.  The merger of these two 
companies made ViaCell’s mission: 
To provide pharmaceutical grade cellular medicines for the treatment of 
human diseases, such as cancer, certain genetic disorders, organ transplant 
tolerance, and autoimmune diseases.  “The research and development arm 
of t. Breeders combined with the commercialized service of Viacord will 
catalyze the development and delivery of new cellular medicines to the 
marketplace,” said Morey Kraus, Chief Technical Officer of ViaCell 
(Craig, 2000). 
 
ViaCell has an Investigational New Drug (IND) application approved by the FDA 
and is initiating a Phase I/II clinical trial for testing of its proprietary selective 
amplification technology.  
 
ViaCell’s Selective Clonogenic AmplificationTM 
ViaCell’s Expansion Technology involves amplifying the number of stem cells 
present in a given sample to end up with a higher yield.  t. Breeders (now ViaCell) has 
developed a process called Selective Clonogenic AmplificationTM, which enables 
simultaneous selection and amplification of stem cells from bone marrow, 
mobilized peripheral blood, or cord blood through the use of highly 
specific markers on stem cells and creating culture conditions that foster 
the outgrowth of stem cells.  In the strict sense, t. Breeders’ Selective 
Clonogenic Amplification is a process for “breeding” cells, i.e., selecting 
preferred events of biological fission to produce target populations from 
among a variety of irrelevant derivative populations (t. Breeders, 2000).    
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This amplification process uses a sample of bone marrow, peripheral blood, or umbilical 
cord blood from either the patient (autologous) or a donor (allogeneic) (t. Breeders, 
2000).  The features of this system include: 
• Removal of differentiated cells and their by-products during cell culture; 
• Production of highly defined target cell populations; 
• Active purging of co-isolated cancer cells; and, 
• Efficient, cost-effective production (t. Breeders, 2000). 
 
 
        
Figure 8. Negative Selection Process. 
(Zimmerman, 1998) Shown is the removal of unwanted CD4+ T-cells. 
 
 
This technique (shown in Figure 8) is especially needed for stem cell replacement 
therapy (SCRT). It uses a cocktail of antibodies that binds to mature and differentiated 
surface cell markers from the mononuclear cell population (Piascik, 2001).  A 
subpopulation of cord blood mononuclear cells termed CD34+/CD38-/Lin- cells that is 
believed to contain stem cells results from this separation process.  These Lin- cells are 
defined as those that lack CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and 
glycophorin A.  These markers are expressed on the surface of mature red blood cells, 
 18 
monocytes, natural killer cells, and T-cells.  The hope of ViaCell, Inc. is that these 
CD34+/CD38-/Lin- cells are in fact primitive hematopoietic stem cells completely 
depleted of mature T-cells, which can cause GVHD.  The FDA has approved the 
initiation of clinical trials for engraftment into human cancer patients.  ViaCell’s 14-day 
expansion process is shown in Figure 9.  After amplification of the UCSC’s from one 
cord, ViaCell believes that these cells now have the capability of reconstituting a 200-kg 
person(s), instead of a 20-kg child before amplification; this needs to be proven 
clinically.  
Figure 9.  UCB cell selection and amplification process time course. 
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PROJECT PURPOSE 
 
 
The purpose of this thesis was to use molecular analyses to analyze gene 
expression patterns in ViaCell’s cellular products.  When the RNA analyzed was 
previously known to be a marker for HSCs (i.e. CD117) the analysis provides a new way 
to validate ViaCell’s product.  For other RNAs shown to be elevated in cell populations 
enriched for HSCs, the analysis provides the identification of new potential HSC 
markers, or growth factors that can stimulate HSC growth during amplification.  
Umbilical cord blood samples from all stages of the amplification process were obtained 
from ViaCell and used to isolate total cellular RNA. mRNA candidates increased in cell 
populations enriched for stem cells were first identified using hybridization arrays then 
confirmed by RT-PCR. Restriction mapping confirmed RT-PCR amplicons.  Finally, one 
specific HSC marker, CD117, was further investigated using Western blots.  
The identification of new markers for HSCs besides CD34+ is important to further 
validate cell products to be perfused into a patient.  A molecular analysis also offers the 
potential to identify new HSC markers or growth factors that would not necessarily be 
detectable in whole UCB.   
 
Introduction to Atlas Arrays 
 
 Atlas Arrays (Clontech) are a type of microarray, specially designed to perform 
hybridization experiments to enable gene profiling.  The history of microarrays began 25 
years ago with the Southern blot, a technique which introduced the principle of anchoring 
nucleic acids to a solid support for analysis by hybridization, and the use of the blots to 
screen filter lifts of bacterial clones (Qiagen, 2000).  Nylon-filter-based arrays rely on the 
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same principles, but use synthetic cDNAs instead of bacterial colonies (Qiagen, 2000).   
The filter array is densely packed with sample dots of known sequences of cDNA, 
making it possible to study the potential expression of thousands of known genes in one 
single hybridization (www.clontech.com). 
  Microarrays offer a number of advantages over other approaches to gene 
expression analysis, since this approach allows small hybridization volumes, high array 
densities, and the use of fluorescence labeling and detection schemes (Schena et al., 
1996).  In addition, a study performed by Schena et al. (1996) concluded that microarrays 
can also be used to analyze the expression of unknown genes when attached clones are 
chosen at random from any library of interest.  Therefore, microarrays may allow rapid 
mechanistic examination of hormones, drugs and other small molecules.  For example, 
functional analysis of growth factors, cytokines and receptors should also be possible 
(Schena et al., 1996).  cDNA microarrays have already been used to profile complex 
diseases such as rheumatoid arthritis, melanoma and Ewing’s sarcoma (Lueking et al., 
1999). 
 Many commercially available types of microarrays are on the market.  Genemed 
Biotechnologies, Inc. sells the Star Profiler™ Array, which allows accurate, reproducible 
gene expression profiles.  Clontech sells the Atlas™ cDNA Expression Array which 
contains hundreds of carefully selected, well-characterized cDNAs.  Because we were 
specifically interested in analyzing potential changes in cytokine expression, and 
Clontech offered a special filter containing 268 carefully chosen cytokine synthetic 
cDNAs, we chose Clontech as our commercial source. 
  MATERIALS AND METHODS 
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Cord Blood Samples 
 
 Human umbilical cord blood samples were donated to ViaCell Inc. from UMass 
Memorial Hospital.  When RNA was to be isolated, cells were usually pooled from 3 
different donors to provide enough material (>107 CD45+ cells) to obtain a good yield of 
total cellular RNA.  When cell lysates were to be made for immunoblot analysis, aliquots 
from single cords containing 105 CD45+ cells were used.  Cells were cultured in Stem 
Span Medium (Stem Cell, Vancouver B.C., Cat# 09650) supplemented with Chemically 
Defined Lipid (0.2% final concentration) (Gibco, Cat#11905-031) and gentamycin (0.1% 
final concentration) (Mediatech, Cat#30-005-CR).  Before being transported to WPI, the 
cultured cells were concentrated by centrifugation and left in an aliquot of original 
culture media.    The cells were then transported to WPI on ice. 
 
Isolation of Total Cellular RNA 
 Total cellular RNA was isolated from 1-3 x 107 CD45+ cord blood cells using the 
Clontech Atlas Pure Total RNA Labeling System (#K1038-1).  Cells were centrifuged at 
12,000 rpm (Sanyo Micro Centaur) for 15 seconds at 4°C, and the supernatant was 
discarded.  A volume of 1 ml of denaturing solution was added to the cell pellet, and the 
solution was separated into two 1.5-2 ml eppendorf tubes (0.5 ml per tube).  Cells were 
resuspended by pipetting up and down, and vortexing.  The lysate solution was incubated 
on ice for 5-10 minutes.  After vortexing the solution again, the lysate was 
microcentrifuged at 12,000 rpm (Sanyo Micro Centaur) for 5 minutes at 4°C to remove 
cellular debris.  The entire supernatant was then transferred to new 2 ml centrifuge tubes 
(0.5 ml per tube), and 1 ml of TE-saturated phenol (i.e. 2 volumes) was added to each 
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tube.  The tubes were capped securely, vortexed vigorously, and incubated on ice for 5 
minutes.  Next, 0.3 ml of chloroform (i.e. 0.6 original volumes) was added per tube, and 
the sample was shook and vortexed vigorously for 1-2 minutes.  It was then incubated on 
ice for another 5 minutes.  The organic/aqueous mixture was microcentrifuged at 12,000 
rpm for 10 minutes at 4°C, and the upper aqueous phase containing the RNA was 
transferred to new tubes, making sure not to pipet any material from the white interphase 
or lower organic phase.  A second round of the phenol: chloroform extraction was 
performed on the aqueous phase using 0.8 ml of phenol and 0.3 ml of chloroform per 
tube.  The twice extracted upper aqueous phase was then transferred to new tubes, and 1 
ml of isopropanol was added per tube.  The sample was mixed, incubated on ice for 10 
minutes, and then microcentrifuged at 12,000 rpm for 15 minutes at 4°C to pellet the 
RNA.  Supernatants were immediately removed without disturbing the RNA pellets.  A 
volume of 0.5 ml of 80% ethanol was then added per tube; the tubes were inverted 
several times, then microcentrifuged at 12,000 rpm for 5 minutes at 4°C to again pellet 
the RNA.  Immediately the supernatant was carefully discarded, and the RNA pellet was 
air-dried (usually for 10 min).  The pellets from both tubes were resuspended in a total of 
50 µl of RNase-free dH2O.  In order to assess RNA yield, 5 µl of sample was added to 1 
ml of dH2O, and the absorbance was taken at 260 nm.  Calculations were based on the 
assumption that 1 OD260 in a 1 cm light path = 40 µg/ml RNA.  The remaining sample 
was aliquotted and stored at -70°C.  
 
Microscale RNA Isolation 
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 This protocol was used when the cell sample received was below 107 cells.  The 
procedure was as described above except for the following.  All of the reagent volumes 
were used at ¼ of the above stated volumes.  Only one round of the phenol: chloroform 
extraction was performed.  Also, when separating the upper aqueous layer from the white 
interphase and lower organic phase, 1 µl of glycogen was added to the sample as a 
“carrier” for the RNA in the sample.  This glycogen provides us with a visible pellet after 
performing the alcohol precipitation, making it harder to accidentally remove the hard to 
see RNA pellet.  The glycogen does not absorb UV light and therefore does not hinder 
RNA quantitation from the spectrophotometer.   
 
DNase Treatment of Total Cellular RNA 
 
 The following reagents were combined in a 1.5 ml microcentrifuge tube for each 
sample to make a 100 µl reaction:  50 µl Total RNA (1 mg/ml), 10 µl 10X DNase I 
Buffer, 5 µl DNase I (1 unit/µl), and 35 µl deionized H2O.   This reaction(s) was 
incubated at 37°C in an air incubator for 30 minutes.  A volume of 10 µl of 10X 
Termination Mix was added and the solution was mixed well by pipetting.  In order to 
make a final volume of 550 µl, 440 µl of deionized H2O was added to the tube.  A 
volume of 500 µl of saturated phenol and 300 µl of chloroform was added, and the tube 
was vortexed thoroughly.  In order to separate the phases, the sample was 
microcentrifuged at 13,000 rpm (Sanyo Micro Centaur) at 4°C for 10 minutes.  The top 
aqueous layer was carefully transferred to a fresh 1.5 ml microcentrifuge tube while 
trying not to pipet any material from the interface or lower phase of the sample.  A 
volume of 550 µl of chloroform was added.  Tubes were vortexed thoroughly, then 
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microcentrifuged at 13,000 rpm at 4°C for 10 minutes to separate the phases.  The top 
aqueous layer was transferred to a new 2 ml microcentrifuge tube.  A volume of 50 µl of 
2M NaOAc and 1.5 ml of 100% ethanol was added, vortexed, and samples were 
incubated on ice for 10 minutes.  The sample was then spun in a microcentrifuge at 
13,000 rpm at 4°C for 15 minutes to pellet the RNA.  The supernatant was carefully 
removed without disturbing the pellet and 500 µl of 100% ethanol was added.  The 
sample was microcentrifuged at 13,000 rpm at 4°C for 5 minutes and the supernatant was 
then carefully removed.  The RNA pellet was then air dried for approximately 10 minutes 
and the precipitate was dissolved in 50 µl of RNase-free dH2O.  RNA yield was 
determined as previously described.  The remaining sample was stored at -70°C. 
 
Assessing the Yield and Purity of Total RNA 
 
 In order to assess the yield and purity of the total RNA samples, a denaturing 
agarose gel was prepared and run.  First, a mini-gel box and combs were thoroughly 
washed with deionized water.  A 250 ml beaker containing a magnetic stir-bar was 
obtained, and 1 g of agarose was weighed and mixed with 82.5 ml of water.  The solution 
was heated in a microwave oven for 2 minutes and placed on a magnetic stir-plate to stir 
slowly for 2 minutes to cool.  While the solution was stirring, 10 ml of 10X MOPS buffer 
and 7.5 ml of formaldehyde were added.  The stirring was continued for 1 minute, then 
the solution was poured into the gel tray.  The gel was left to solidify at room temperature 
for 1 hour, then the gel comb was removed and the gel was submerged in the gel box 
with 1X MOPS buffer.   
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 The RNA loading solution was prepared immediately before running the gel by 
mixing the following (for 6-10 samples): 45 µl of formaldehyde, 45 µl deionized 
formamide, 10 µl 10X MOPS buffer, 3.5 µl EtBr (10 mg/ml), 1.5 µl 0.1M EDTA (pH 
7.5), and 8 µl 10X bromophenol blue dye (in 50% glycerol).  A volume of 15 µl of RNA 
loading solution was added to 2 µg (usually 2 µl) of total RNA and mixed well.  The 
solution was heated at 70°C for 15 minutes and cooled on ice for 1 minute.  The sample 
solution was then loaded onto the gel, and electrophoresed at 50-60V until the blue dye 
reached the midpoint of the gel tray.    RNA was visualized on a UV transilluminator. 
 
cDNA Probe Synthesis 
 Probe synthesis from total cellular RNA was performed using Clontech’s Atlas 
cDNA Expression Array Protocol (#PT3140-1).  First, a Master Mix was prepared for all 
labeling reactions.  The following reagents were combined in a 0.5-ml microcentrifuge 
tube at room temperature for each sample of RNA: 2 µl of 5X Reaction Buffer, 1 µl of 
10X dNTP Mix, 3.5 µl of [α-32P]dATP (3,000 Ci/mmol), and 0.5 µl of DTT.  Then, a 
PCR thermocycler was preheated to 70˚C.  For each reaction, 2 µl RNA (usually 
containing 2 µg) and 1 µl CDS Primer Mix (a special combination of primers designed 
specifically for the Atlas filter) were combined in a labeled 0.5-ml PCR tube.  Next, the 
tubes were mixed well by pipetting, and spun briefly in a microcentrifuge.  Then, these 
tubes were incubated in the PCR thermocycler at 70˚C for 2 minutes.  After 2 minutes, 
the temperature of the thermocycler was reduced to 50˚C, and the tubes were incubated 
for 2 more minutes.  During this incubation, 1 µl MMLV Reverse Transcriptase was 
added per reaction to the Master Mix, it was mixed by pipetting, and incubated at room 
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temperature for 2 minutes.  After the incubation of two minutes was completed, 8 µl of 
Master Mix was added to each ~3 µl reaction sample, ensuring that the RNA samples in 
the 50˚C thermocycler were not removed for longer than was necessary to add the Master 
Mix.  The contents of the tubes were mixed by pipetting and then immediately returned 
to the thermocycler.    The tubes were then incubated in the PCR thermocycler at 50˚C 
for 25 minutes.  After incubation, 1 µl of 10X Termination Mix was added to each tube.  
The tubes were stored on ice until column chromatography. 
 To purify the labeled cDNA from unincorporated 32P-labeled nucleotides and 
small cDNA fragments, the following procedure was performed.  Before using the Buffer 
NT3, 15 ml of 95% ethanol was added to the bottle.  First, the probe synthesis reactions 
were diluted by adding 190 µl of Buffer NT2.  Second, a NucleoSpin Extraction Spin 
Column was placed into a 2-ml Collection Tube, and the sample was pipetted into the 
column.  The tube was then microcentrifuged at 14,000 rpm for 1 minute.  The Collection 
Tube and the flowthrough containing the waste were then discarded into the appropriate 
container for radioactive waste.  Then, the NucleoSpin column was inserted into a fresh 
2-ml Collection Tube, and 400 µl of Buffer NT3 wash was added to the column.  The 
sample was microcentrifuged at 14,000 rpm for 1 minute, and the tube and flowthrough 
were discarded again.  The addition of Buffer NT3 wash and the centrifugation steps 
were repeated twice more.  The NucleoSpin column was then transferred into a clean 1.5-
ml microcentrifuge tube, 100 µl of elution Buffer NE was added, and the column was 
allowed to soak for 2 minutes.  The tube was microcentrifuged at 14,000 rpm for 1 
minute to elute the purified cDNA probe.  The approximate radioactivity of the liquid 
eluted into the microcentrifuge tube versus that remaining in the column were assessed 
 27 
using a Ludlum hand-held Geiger counter to monitor efficient elution from the column.  
The counts should be higher in the eluate tube than in the column, otherwise the elution 
was repeated. 
 
Probe Hybridization 
 Hybridization of cDNA probe to the Atlas Array filter was performed using 
Clontech’s Atlas cDNA Expression Array Protocol (#PT3140-1).  First, 5 ml of 
ExpressHyb was prewarmed at 68˚C.  Next, 50 µl (0.5 mg) of sheared salmon testes 
DNA was heated at 97˚C for 5 minutes to denature the DNA, then quickly chilled on ice 
to prevent snap-back.  Then, the denatured salmon testes DNA and the 5 ml prewarmed 
ExpressHyb aliquot were mixed, and kept at 68˚C.  A Tupperware container was filled 
with deionized water and the Atlas Array (catalog #7744-1, stored at -20˚C) was placed 
in the Tupperware to wet it.  All the water was then poured off and 5 ml of the 68˚C 
testes DNA/ExpressHyb solution was added to the membrane.  This step was performed 
quickly to ensure that the membrane would not dry.   Then, the membrane was 
prehybridized for 30 minutes with continuous agitation at 68˚C in an air incubator.  Next, 
the probe was prepared for hybridization by adding 5 µl Cot-1 DNA (1 mg/mL) to the 
entire 100 µl pool of labeled probe.  The probe was then incubated in a boiling water bath 
for 2 minutes to denature it, and incubated on ice for 2 minutes.  This mixture was added 
to the prehybridization solution and membrane in the Tupperware, ensuring that the 
probe was not directly added to the membrane, and that the two solutions were 
thoroughly mixed together.  The membrane was then hybridized overnight with 
continuous agitation at 68˚C.  If necessary, 2-3 ml of extra prewarmed ExpressHyb was 
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added to the solution to ensure that the entire membrane was in contact with 
hybridization solution at all times. 
 The next day, Wash Solution 1 and Wash Solution 2 were prewarmed at 68˚C. 
The hybridization solution was discarded in an appropriate radioactive waste container, 
and was replaced with 200 ml of prewarmed Wash Solution 1.  The membrane was 
washed for 30 minutes with continuous agitation at 68˚C.  This process was repeated 
three more times.  Then, one 30-minute wash was performed using 200 ml of prewarmed 
Wash Solution 2 with continuous agitation at 68˚C.  One final 5-minute wash was 
performed in 200 ml of 25˚C 2X SSC with agitation at room temperature.  Using forceps, 
the membrane was removed from the container, and the excess Wash Solution was 
shaken off, never allowing the membrane to dry.  The membrane was immediately 
wrapped in a plastic bag and sealed with a bag sealer.  Finally, the membrane was 
exposed to BioMax x-ray film at -70˚C with an intensifying screen for varying lengths of 
time (3- and 5-day exposures).  When the exposure was complete, the membrane was 
kept wrapped in plastic, and stored at -20˚C until stripped for re-use.  In our hands, 
membranes could only be used a total of 3 times. 
 
Probe Removal  
To strip the cDNA probes from the membrane, 500 ml of 0.5% SDS solution was 
heated to boiling in a 2-L beaker.  Then the membrane was removed from the plastic bag, 
and placed in the boiling solution for 5-10 minutes.  The SDS solution was then removed 
from the heat and allowed to cool for 10 minutes.  The Atlas Array filter was then 
removed from the solution and immediately re-wrapped in a new plastic bag and sealed.  
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To ensure the stripping procedure was effective, the membrane was checked with the 
hand-held Geiger counter, and by exposure to x-ray film for 3 days.  Once the efficacy of 
the stripping was verified, the membrane was stored at -20˚C until needed. 
 
RT-PCR 
Reverse Transcription 
 RT-PCR was performed to verify the upregulation of candidates identified from 
the arrays.  Buffers, Taq polymerase, RT, and RNase Inhibitor were purchased from 
Ambion.  Primers for these candidates were ordered from IDT based on sequences 
provided by Clontech.  Each reaction was performed in a 0.5-µl-eppendorf tube.  First, 2 
µg of total cellular RNA (usually 2 µl) was added to 5µM (2 µl of a 50 µM stock) of the 
antisense primer and brought up to 12 µl with nuclease-free dH2O.  The tube(s) was then 
mixed, spun briefly, and heated for 3 minutes at 85˚C.  The tube(s) was then removed to 
ice, spun briefly, and the following components were added (for each 12 µl sample to 
make a 20 µl reaction volume):  2 µl of 10X RT Buffer, 4 µl of dNTP mix, 1 µl of RNase 
Inhibitor, and 1 µl (100 units) of Reverse Transcriptase (a negative control that lacks 
Reverse Transcriptase should also be included when RT-PCR is performed).  The tube(s) 
was then mixed gently, spun briefly, and incubated at 44˚C for one hour.  Once the hour 
was over, an additional incubation period of 10 minutes at 92˚C inactivated the Reverse 
Transcriptase.  These reactions were either stored at -20˚C or analyzed by agarose 
electrophoresis. 
 
PCR 
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 The following components were mixed in a separate tube for each PCR reaction, 
5 µl of the RT reaction described above, 5 µl of 10X PCR buffer, 2.5 µl of dNTP mix, 
and nuclease-free dH2O to make 50 µl.  Then the following were added: 2.5 µl of 50 µM 
sense primer and 0.4 µl (2 U) of Thermostable DNA Polymerase.    The templates were 
denatured by heating the samples at 94˚C for 2 minutes.  The samples were incubated for 
30 cycles of 94˚C for 30 seconds, 55˚C annealing for 30 seconds, and 72˚C elongation for 
40 seconds.  After these 30 cycles, a final polishing extension for the samples was at 
72˚C for 5 minutes.  The tube(s) were held in the thermocycler for 4˚C until the next day, 
stored at -20˚C, or analyzed by agarose gel analysis of RT-PCR products.   
 
Analysis of RT-PCR Products 
 To analyze the RT-PCR products, a 1X dye buffer at 1/10th the volume of RT-
PCR product (approximately 5 µl) was added.  A 10 µl aliquot of the 50 µl reactions were 
loaded into the wells of a 2.5% agarose gel containing 0.5 µg/ml of ethidium bromide and 
1X TAE.  The marker λ/Pst I (10 µl of 0.2 µg/µl stock) was used to determine the size of 
the bands produced.  The remainder of the reactions were stored at -20˚C.   
 
Western Blotting 
Preparation of Whole Cell Lysates 
 The microcentrifuge tube(s) containing the cell samples (107 CD45+ cells) 
were microcentrifuged for 15 seconds at 12,000 rpm (Sanyo Micro Centaur) at 4°C to 
pellet the cells.  The supernatant (medium) was discarded, and this centrifugation was 
repeated to thoroughly remove all liquid.  A volume of 200 µl of CHAPS lysis buffer (10 
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mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM β-
mercaptoethanol, 0.5% CHAPS, 10% Glycerol, supplied from Intergen #S7700) was 
added per pellet.  The cells were resuspended by gently pipetting up and down. The 
tube(s) were then incubated on ice for 30 minutes and microfuged at 12, 000 rpm for 20 
minutes at 4°C to pellet cell debris.  Cleared lysates were aliquotted and stored at -80°C. 
 
Western Gels 
 Western Blots were performed to analyze protein upregulations.  First, a lower 
resolving gel (10% Acrylamide, 0.38 M Resolving Gel Buffer, 0.1% SDS, 0.1% 
Ammonium Persulfate, 0.05% TEMED, and dH2O) was made and polymerized for 20 
minutes.  Next, an upper stacking gel (5% Acrylamide, 0.125 M Stacking Gel Buffer, 
0.1% SDS, 0.1% Ammonium Persulfate, 0.1% TEMED, and dH2O) was added and 
polymerized for 20 minutes or overnight.  
 Whole cell lysates (15 µl) were added to 5 µL 4X protein sample buffer (dH2O, 
0.5 M Stacking Gel Buffer, 8% SDS powder, 20% glycerol, 40% β-mercaptoethanol, 
0.4% bromphenol blue powder).  The samples were boiled for 2 minutes, loaded onto the 
gel, and electrophoresed for about 3 hours at 150 V.   
 
Antibody Binding 
Next the gels were electrically transblotted onto a Nitrocellulose membrane (BA-
45, 0.45 µm), placed in blocking solution (1X PBS pH 7.5, 1% Casein, 0.2% Tween-20, 
and dH2O) for 1 hour, and then 20 µl of primary antibody (mouse anti-human CD117, 
BD PharMingen catalog # 555713) in 10 ml of blocking solution was added and left to 
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incubate at 25°C on a rocker overnight.  Subsequent washes were as follows.  A volume 
of 50 mL of 1X PBS-Tween was added to the membrane and incubated at 25°C for 5 
minutes.  This wash was repeated 3 times.  The wash solution was removed and 10 µl of 
secondary antibody (goat anti-mouse IgG conjugated to HRP) in 10 ml of blocking 
solution was added and incubated at 25°C for 2 hours.  A subsequent wash was 
performed as stated above.  Chemiluminescence (5 ml Luminol/Enhancer Solution plus 5 
ml of Stable Peroxide Solution, Pierce # 34080) was used to detect the HRP on the 
membrane.  Membranes were exposed to X-ray film for 30 minutes (with an intensifying 
screen) and developed as usual using GBX developer.    
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RESULTS 
 
 
 The goal of this project was to determine which cytokine mRNAs were 
upregulated or downregulated during ViaCell’s stem cell amplification treatment.  A 
hybridization array assay was chosen as a preliminary screen because of its speed in 
screening hundreds of candidates at one time.  Clontech was chosen as a commercial 
source for the array filter because they offer an array (cat# 7744-1) with 268 carefully 
chosen cytokine and cytokine receptor cDNAs.   
 In a hybridization array assay, a population of cDNAs is synthesized from total 
cellular RNA or poly(A)+ mRNA by reverse transcriptase.  During the synthesis reaction, 
the cDNAs can be radiolabeled or biotinylated.  This cDNA population is then hybridized 
to a filter containing attached cDNAs representing a variety of known mRNAs.  The 
filter-attached cDNAs are often short synthetic oligos unique to each mRNA.  With the 
Clontech arrays the cDNA dots are pre-spotted in duplicates.  Following hybridization, 
the filter is washed, then exposed for autoradiography or chemiluminescence.  The 
intensity of each dot signal on the film reflects the abundance of the corresponding 
mRNA in the original RNA sample. 
 For this project we chose to synthesize cDNAs from total cellular RNA instead of 
poly(A)+ RNA because the former is more likely to be isolated intact from a tissue 
(blood) rich with nucleases.  We also chose to radiolabel the cDNAs with 32P because it 
gives more reliable signals in our hands. 
 
 
FACS Analysis of Day-0 and Day-14 Cells 
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 Umbilical cord blood cell samples obtained from ViaCell for RNA analysis 
represent day-0 and day-14 samples. When day-0 is referred to (see Table 3), it 
represents a set of un-amplified, un-selected CD45+ cells containing little or no red blood 
cells.  Day-14 cell samples represent cells that have undergone two column selections 
and amplification in the presence of added growth factors.  Samples obtained for Western 
analysis came from all points of the amplification process.  
 
Fraction % CD34+/CD38- 
Pre-Freeze (Day-0) 0.26 
Pre-Sep 1 0.17 
Post-Sep 1 (Day-0.5) 3.20 
Pre-Sep 2 31.25 
Post-Sep 2 33.20 
Cell Product (Day-14) 10.53 
Thawed Cell Product (Day-
14.5) 
11.54 
Table 3. Percent of CD34+/CD38- cells at each stage of the amplification process. 
 
 “Pre-freeze” (or day-0) samples are fresh mononuclear cells and contain about 
0.26% of what ViaCell defines as hematopoietic stem cells.  The cell population before 
the first separation step of the amplification process is termed “pre-sep 1” and contain 
0.17% HSCs.  The cell population after the first round of separation is termed “post-sep 
1” and contains 3.20% HSCs.  The cells then undergo a week of growth in culture and are 
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termed “pre-sep 2” right before the second separation (containing about 31.25% HSCs).  
After the second round of separation, the cells are termed “post-sep 2” and contain 
33.20% HSCs.  After undergoing a second week of growth in culture they are termed 
“cell product” or (day-14) and contain 10.53% HSCs.  Cells are frozen for storage and 
thawed (then termed “thawed cell product) and contain 11.54% HSCs. 
 
RNA Isolation and Integrity 
 The first phase of this project was to isolate total cellular RNA from human cord 
blood samples.  Pooled cord samples (usually 3) were obtained from ViaCell, and RNA 
was isolated by a modified phenol extraction procedure (see Methods).  Table 4 
summarizes the cord blood samples obtained from ViaCell, the number of cells, and the 
corresponding RNA yield after the isolation procedure.   
Table 4.  Cord Cell Numbers and Corresponding RNA Yields. 
Date  Sample  CD45+ Cell #'s 
Microscale 
technique? 
RNA yield 
(µg) Conc. (µg/µl) 
12/1/00 Day 0 2x10^6 no 6.8 0.136 
12/6/00 Day 0 8.51x10^7 no 58.40 1.170 
12/12/00b Day 14 *1.3x10^8 no 322.40 6.450 
12/15/00a Day 0 *7.30x10^8 no 83.60 1.670 
12/15/00a Day 14 *2.17x10^8 no 148.40 2.970 
12/15/00b Day 14 *2.17x10^8 no 114.40 2.290 
2/14/01a Day 14 *7.79x10^7 no 123.60 2.470 
2/14/01b Day 14 *7.79x10^7 no 149.20 2.980 
9/6/01a Post Thaw *2.6x10^7 no 2.00 0.040 
9/6/01b Post Thaw *2.6x10^7 no 1.60 0.032 
9/7/01a Pre-Sep 1 *5.6x10^7 no 6.80 0.136 
9/7/01b Pre-Sep 1 *5.6x10^7 no 10.40 0.208 
9/10/01a Post Thaw *approx.3.0x10^8 no 46.00 0.920 
9/10/01b Post Thaw *approx.3.0x10^8 no 46.40 0.928 
9/13/01a Day 0 *approx.4.0x10^8 no 49.60 0.992 
9/13/01b Day 0 *approx.4.0x10^8 no 36.80 0.736 
9/13/01c Day 0 *approx.4.0x10^8 no 21.60 0.432 
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Table 4, continued. 
 
Date  Sample  CD45+ Cell #'s 
Microscale 
technique? 
RNA yield 
(µg) Conc. (µg/µl) 
9/13/01 Day 14 2x10^6 yes 6.40 0.128 
9/14/01a Pre-Sep 1 *approx.1.0x10^8 no 8.40 0.168 
9/14/01b Pre-Sep 1 *approx.1.0x10^8 no 14.00 0.280 
9/14/01a Pre-Sep 2 *approx.1.0x10^7 no 43.20 0.864 
9/14/01b Pre-Sep 2 *approx.1.0x10^7 no 38.00 0.760 
9/17/01a Day 0 *approx.1.0x10^8 yes 14.80 0.296 
9/17/01b Day 0 *approx.1.0x10^8 yes 90.40 1.808 
9/17/01c Day 0 *approx.1.0x10^8 yes 38.80 0.776 
9/17/01d Day 0 *approx.1.0x10^8 yes 110.40 2.208 
9/17/01e Day 0 *approx.1.0x10^8 yes 82.40 1.648 
9/17/01f Day 0 *approx.1.0x10^8 yes 132.80 2.656 
9/17/01g Day 0 *approx.1.0x10^8 yes 72.80 1.456 
9/17/01h Day 0 *approx.1.0x10^8 yes 74.00 1.480 
9/18/01a Day 0 4ml off 1 cord yes 102.40 2.048 
9/18/01b Day 0 4ml off 1 cord yes 36.40 0.728 
9/20/01a Day 0 4ml off 1 cord yes 9.60 0.192 
9/20/01b Day 0 4ml off 1 cord yes 3.60 0.072 
9/25/01a Day 0 ~10^6 yes 9.60 0.192 
9/25/01b Day 0 ~10^6 yes 33.60 0.672 
9/27/01a Post Thaw 4.5x10^6 yes 1.60 0.032 
9/27/01b Post Thaw 1.2x10^6 yes 0.40 0.008 
9/27/01c Post Thaw 4.68x10^6 yes 0.80 0.016 
9/27/01d Post Thaw 6.75x10^6 yes 1.20 0.024 
9/28/01a Pre-Sep 1 5.10x10^6 yes 17.20 0.344 
9/28/01b Pre-Sep 1 1.02x10^6 yes 8.00 0.160 
9/28/01c Pre-Sep 1 5.45x10^6 yes 10.00 0.200 
9/28/01d Pre-Sep 1 8.95x10^6 yes 6.00 0.120 
10/01/01a Day 0 6.9x10^6 yes 10.80 0.216 
10/01/01b Day 0 3.2x10^6 yes 28.00 0.560 
10/01/01c Day 0 3.04x10^6 yes 38.80 0.776 
10/01/01d Day 0 2.56x10^6 yes 163.60 3.272 
10/04/01a Post Thaw 3.40x10^6 yes 4.40 0.088 
10/04/01b Post Thaw 2.62x10^6 yes 4.40 0.088 
10/04/01c Post Thaw 3.64x10^6 yes 6.40 0.128 
10/05/01a Pre-Sep 1 3.99x10^7 yes 4.00 0.080 
10/05/01b Pre-Sep 1 1.24x10^8 yes 1.20 0.024 
10/05/01c Pre-Sep 1 5.93x10^7 yes 6.40 0.128 
10/05/01d Pre-Sep 1 ~10^8 yes 16.00 0.320 
10/12/01a Pre-Sep 2 2x10^6 yes 4.40 0.088 
10/12/01b Pre-Sep 2 1.34x10^6 yes 1.20 0.024 
10/12/01c Pre-Sep 2 1.01x10^6 yes 2.00 0.040 
10/12/01a Post-Sep 2 2x10^6 yes 2.40 0.048 
10/12/01b Post-Sep 2 1x10^6 yes 0.00 0.000 
10/16/01a Day 14 9.20x10^5 yes 0.80 0.016 
10/16/01b Day 14 1.03x10^6 yes 1.60 0.032 
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Table 4, continued. 
 
Date  Sample  CD45+ Cell #'s 
Microscale 
technique? 
RNA yield 
(µg) Conc. (µg/µl) 
10/17/01a       Day 14 *9.10x10^6 yes 16.40 0.328 
10/17/01b Day 14 *9.10x10^6 yes 8.00 0.160 
10/17/01c Day 14 2.56x10^6 yes 2.80 0.056 
10/19/01a Day 14 1.87x10^7 yes 91.20 1.824 
10/19/01b Day 14 8.23x10^6 yes 27.60 0.552 
10/25/01a 
Day 14- 
thawed 2.70x10^6 yes 8.40 0.168 
10/25/01b 
Day 14- 
thawed 2.80x10^7 yes 145.20 2.904 
10/26/01a 
Day 14- 
thawed 5.98x10^6 yes 56.80 1.136 
10/26/01b 
Day 14- 
thawed 1.50x10^7 yes 20.80 0.416 
3/11/02 Day-0 1.0x10^7 yes 11.6 0.232 
3/25/02 Day-14 1.0x10^7 yes 18.4 0.368 
                  
As can be seen in the Table, the final yield of RNA did not correlate with the total CD45+ 
cells received, therefore the status of the cords could have been a factor affecting yield. 
In order to determine which RNA samples were intact following the RNA 
isolation protocol, denaturing formaldehyde agarose gel electrophoresis was performed.  
Discrete 28S and 18S ribosomal RNA bands were used as evidence of intact RNA.  
Figure 10 displays an example of an RNA integrity gel.  The 28S and 18S ribosomal 
RNA bands can clearly be seen.  Samples in lanes 2 and 3 were not taken for further 
analysis. 
 
Lane 1   2   3   4   5  6   7   8   9 10 11 12 
 
 
 
Figure 10. RNA integrity gel. 
18S 
28S 
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Extraction procedures used for isolating total cellular RNA sometimes co-isolate 
trace amounts of DNA.  This contaminating DNA is capable of being radiolabeled during 
probe preparation, so DNase treatment was performed on two cord RNA samples.    The 
reason all samples were not DNase treated was because the RNA yield fell to 0 µg after 
the treatment.  Therefore, it was concluded that the Clontech DNase treatment protocol 
was not an effective way to rid DNA so it was discontinued.  Using the information 
obtained from the RNA gels, it was possible to determine which RNA samples were most 
intact and likely to give the best hybridization results.   
 
Hybridization Arrays for Day-0 Cells 
Day-0 cord cells represent un-amplified, un-selected CD45+ (non RBC) cord 
cells.  The Atlas Array (Clontech, cat# 7744-1) chosen for this experiment contained 268 
known cytokine and cytokine receptor cDNAs.  Figure 11 shows the result of 
hybridization 1-29-01 of day-0 cDNA synthesized from cord RNA isolated on December 
15, 2000, tube a.  All dots are in duplicate on the membrane and equal signals were 
observed for all duplicate dots.  The membrane on the right hand side of the figure is 
overlaid with a grid provided by Clontech to identify the dots.     
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 Figure 11. Trial 1, Hybridization Array for the First Sample of Day-0 Cells. 
Results from the 9-day exposure on XAR-5 film of the Day-0 cord sample. From 
RNA isolated on December 15, 2000, tube a. The membrane on the right contains a 
grid in order to identify the cytokine mRNAs that are upregulated. 
 
 
 All of the dots seen in column 1 (rows A-I) are “housekeeper” controls.  These 
are present to ensure that the hybridization was complete to the membrane, as well as 
aiding in the alignment of the grid to properly identify the dots.  In Figure 11 
housekeeper mRNAs are seen at positions 1A, 1D, and 1H.  The other housekeepers that 
should have appeared did not in this hybridization, most likely due to the standard XAR-
5 type of x-ray film used (low sensitivity), or due to a low specific activity of the probe.  
Also, the 9-day exposure is longer than usually done according to the Clontech Manual.  
Therefore, in our subsequent hybridizations, BioMax x-ray film was used, as well as a 
higher specific activity probe, which gave us much better results.  Column 1, rows J-L 
are negative controls, and no signal was observed for these.  One interesting finding from 
this figure is that no inflammatory cytokine mRNAs appear to be expressed in the day-0 
RNA.  This lack of inflammatory cytokines could be highly significant if the cord 
 40 
samples are to be reperfused into a patient.  Table 5 (at the end of the hybridization array 
results) summarizes the cytokine mRNAs seen on this membrane. 
To assay intra-sample variability, a second cDNA probe was synthesized from the 
same RNA examined in Figure 11.  The probe was hybridized to the same membrane 
again.  This data (Figure 12) shows us the same dots as in Figure 11, although many more 
are seen, and they are darker.  Obviously, the probe used in this figure was of much 
higher specific activity than the previous figure.  Again, the duplicate dots are identical in 
each case indicating a reproducible signal.  The housekeepers that were the darkest on the 
previous filter were also the darkest here.  All housekeepers are visible on this array 
(column 1, rows A-I).  Therefore, we have concluded that although probe specific 
activity varies from one reaction to another from the same RNA sample, which alters the 
total number of dots observed, the strongest dots remained nearly identical in the 
duplicate determination.  Regarding cytokine mRNAs (and their receptors), strong new 
signals were observed for IL-8 precursor (3J), IL-2-R (4I), Leukocyte interferon-
inducible peptide (6F), calgranulin-A (6H), calgranulin-B (6I), small inducible cytokine 
A5 (7F), and thymosin-β (23H).  Weak or no signals were observed for TNF-α (14I), and 
TNF-R (14J) (14K). 
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 Figure 12.  Trial 2, Hybridization Array for the First Sample of Day-0 Cells. 
 Results from the 5-day exposure on BioMax film of the Day-0 cord sample.  From RNA 
 isolated on December 15, 2000, tube a.  This second trial focuses on day-0 intra-sample  
 variability. 
 
 
Since many different day-0 samples were received from ViaCell, several 
independent observations of day-0 cells could be performed.  Figure 13 shows the 
analysis of a second day-0 sample from RNA isolated on December 6, 2000.   Fewer dots 
are seen here than in Figure 11.  Only 3 housekeepers are visible.  Unlike the previous 
day-0 sample, IL-1-R antagonist protein (4F) was the strongest dot on the filter.  This 
indicates that some significant inter-sample variability can be expected between pooled 
cord samples.   
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32P Hy
         RNA From Day-0 Cells, 5 Day Exposure 
bridization Array Assay 3-1-01 
 
Figure 13.  Trial 1, Hybridization Array for the Second Sample of Day-0 Cells.  
Results from the 5-day exposure on BioMax film of the Day-0 cord sample.  From RNA isolated 
on December 6, 2000.  This trial focuses on day-0 inter-sample variability. 
 
 
To assay intra-sample variability for this second day-0 sample, a second cDNA 
probe was synthesized from the same RNA assayed in Figure 13.  This new cDNA was 
hybridized to the same membrane again after its first probe was removed. Unfortunately 
Figure 14 shows us few of the same dots as in Figure 13, although many more are seen, 
and they are much darker.  Obviously, the probe used in Figure 14 is of much higher 
specific activity than the previous figure.  Again, the duplicate dots are identical in each 
case, and almost all of the housekeepers are seen (although darker in this figure).  We can 
conclude that the RNA assayed in the previous Figure 13 was good, but the cDNA from 
that batch was low specific activity. 
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Figure 14. Trial 2, Hybridization Array for the Second Sample of Day-0 Cells.   
Results from the 5-day exposure on BioMax film of the Day-0 cord sample.  From RNA isolated 
on December 6, 2000.   
 
In order to determine whether different membranes obtained from Clontech were 
identical to each other, we performed another cDNA synthesis on the same RNA isolated 
on December 6, 2000, and hybridized to a new different membrane.    Figure 15 contains 
most of the same dots seen in Figure 14, although some differences were observed.  The 
best way to perform this experiment is to prepare two cDNA reactions from the same 
RNA, pool them, and hybridize to two membranes.  This will be done in future 
experiments.   
We conclude from the array analysis of day-0 cells that although significant 
signal variability results from low and high specific activity probes, when comparing 
only high-specific activity data, the patterns are mostly reproducible. 
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Figure 15. Trial 3, Hybridization Array for the Second Sample of Day-0 Cells. 
Results from the 5-day exposure on BioMax film of the Day-0 cord sample.  From RNA isolated 
on December 6, 2000.  This experiment focuses on membrane-to-membrane production 
variability. 
 
 
Hybridization Arrays for Day-14 Cells 
As was done for the day-0 samples, day-14 samples were also analyzed on arrays.  
Day-14 samples represent cells that have undergone two column selections and cell 
amplification.  Figure 16 shows the results for day-14 RNA isolated on 12/15/00.  Many 
more dots are seen here, especially to the right hand side of the membrane, than was ever 
observed for day-0 samples, in spite of this particular probe being low specific activity 
(few housekeepers are visible).  This area of dots signify some of the developmentally 
important cytokines, as well as growth factors.  If these are subsequently proven to be 
upregulated in RT-PCR assays, it may imply that these “stem” cell enriched populations 
at Day-14 may have in part returned to an undifferentiated state.  Upregulated candidates 
not seen in day-0 samples include frizzled homologs (20L), jagged homologs (21D and 
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21E), wingless-related MMTV protein (20H), and growth factors such as vascular 
endothelial growth factors (19D) and transforming growth factor (15F and 15G).   
 
 
 
Figure 16. Trial 1, Hybridization Array for the First Sample of Day-14 Cells. 
Results from the 9-day exposure on XAR-5 film of the Day-14 cord sample. From RNA isolated 
on December 15, 2000, tube a.   
 
A complete list of the apparently upregulated cytokine mRNAs is seen in Table 5 at the 
end of the hybridization array results.  Some of the strongest dots on the day-14 array 
include mRNAs in common with day-0 samples, including Leukocyte interferon 
inducible peptide (6F), and small inducible cytokine A5 (7F).  As was the case for the 
day-0 samples, no signal was observed for inflammatory cytokine TNF-α (14J). 
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To assay day-14 intra-sample variability, a second cDNA batch from the same 
RNA analyzed in the previous figure (Figure 16) was hybridized to the same membrane 
again after its first probe was removed.  Figure 17 shows the results of this experiment. 
This probe gave the highest number of cytokine dots observed on any array so far under 
conditions in which all but 3 housekeepers are visible.  The resulting darker spots in 
some cases result from the use of stronger probe and film.  For example, the dots seen at 
positions 6F and 7F are strongly seen in both figures, but the dots are darker in Figure 17.  
Figures 16 and 17 show basically the same dot patterns, so this again proves that 
expression patterns are somewhat reproducible when using high-specific activity probes. 
32P Hybridization Array Assay 3-1-01
  RNA From Day-14 Cells, 5 Day Exposure- Trial 2 
 
Figure 17. Trial 2, Hybridization Array for the First Sample of Day-14 Cells. 
Results from the 5-day exposure on BioMax film of the Day-14 cord samples.  From RNA 
isolated on December 15, 2000, tube a. This second trial focuses on intra-sample variability. 
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In the future, we plan to demonstrate this more rigorously by synthesizing one large 
batch of cDNAs from one day-14 sample, then splitting the cDNA sample into halves, 
and hybridizing to two membranes. 
Since many day-14 samples were received from ViaCell, a thorough analysis of 
this cell population was performed.  Figure 18 shows a second day-14 sample from RNA 
isolated on February 14, 2001.  This RNA sample yielded our highest specific activity 
probe to date.   All housekeepers are visible, and many are quite strong.  As observed 
with the first day-14 sample, the membrane contains many more dots than for any day-0 
sample.   
 
32P Hybridization Array Assay 3-1-01 
         RNA From Day-14 Cells, 5 Day Exposure 
Figure 18. Trial 1, Hybridization Array for the Second Sample of Day-14 Cells. 
Results from the 5-day exposure on BioMax film of the Day-14 cord sample.  From RNA 
isolated on February 14, 2001 tube a. This trial enables us to assay inter-sample variability 
relative to the previous figures. 
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This second day-14 sample was reanalyzed for intra-sample variability.  
Unfortunately, this cDNA did not have quite the same high specific activity as trial-1, but 
the pattern of strongest dots is the same.   In each day-14 case, however, more dots are 
seen in these membranes than in any day-0 membranes.  In all cases, the duplicate dots 
have the same intensities. 
 
Figure 19. Trial 2, Hybridization Array for the Second Sample of Day-14 Cells. 
Results from the 5-day exposure on BioMax film of the Day-14 cord sample.   
From RNA isolated on February 14, 2001, tube a.  This second trial analyzes intra-sample 
variability for the second day-14 sample. 
 
Finally, once more in order to determine whether different membranes obtained 
from Clontech were identical to each other, we performed another cDNA synthesis on the 
same RNA isolated on February 14, 2001, and hybridized to a new membrane.  
Unfortunately, Figure 20 shows that a very poor cDNA reaction occurred.  Very few dots 
are seen, including a lack of housekeepers.  Since the same RNA yielded better results in 
previous hybridizations, we can conclude that the cDNA synthesis for trial-3 was most 
likely very weak.  
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 Figure 20. Trial 3, Hybridization Array for the Second Sample of Day-14 Cells. 
Results from the 5-day exposure on BioMax film of the Day-14 cord sample.  From RNA isolated 
on February 14, 2001, tube a.  The lack of dots in this case was most likely due to a poor cDNA 
synthesis and weak hybridization signals.  
 
One additional hybridization was performed with an RNA sample isolated on 
December 15, 2000, tube b.  When the film was exposed, it contained no dots 
whatsoever.  When the RNA integrity was re-analyzed on a denaturing agarose gel, the 
sample displayed a weak 18S band, so perhaps this RNA sample was somewhat 
degraded.   
 
Array Summary 
Table 5 (page 59) summarizes all the hybridization array figures.  The symbol 
+++ signifies a strong signal (dark dots on the membrane), ++ signifies a moderate signal 
(medium dots), + signifies a low signal (light dots), and blank signifies no observable 
signal.  Because signal patterns are so strongly influenced by probe specific activity, our 
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best comparison can be made only between those arrays showing most of the 
housekeepers, i.e. array-5 versus array-8.   
Some mRNAs were commonly represented in day-0 and day-14 samples. These 
include: interleukin-8 precursor, interleukin-10 precursor, interleukin-2 receptor alpha 
subunit precursor, interleukin-6 receptor beta subunit precursor, leukocyte interferon 
inducible peptide, B-cell growth factor-1 precursor, migration inhibitory factor-related 
protein 8, calgranulin-B, small inducible cytokine subfamily B5, small inducible cytokine 
A5, insulin receptor precursor, secreted apoptosis related protein, tumor necrosis factor 
alpha precursor, transforming growth factor beta, transforming growth factor beta-2 
precursor, smoothened homolog, jagged homolog-2, neurogenic locus Notch protein 
homolog-1 precursor, platelet-activating factor receptor, thymosin beta-10, and 
orientation marks.    Each of these cytokines were upregulated at day-0 as well as day-14.   
Some cytokine mRNAs were upregulated greatly at day-14:  interleukin-1 beta 
precursor, interleukin-6 precursor, interleukin-13 precursor, interleukin-1 receptor type II 
precursor, interleukin-2 receptor gamma subunit, interleukin-7 receptor alpha subunit 
precursor, interferon alpha/beta receptor beta subunit, interferon gamma antagonist, 
interferon regulatory factor-1, hepatocyte growth factor-like protein, macrophage-
specific colony-stimulating factor, macrophage inflammatory protein-1 alpha precursor, 
macrophage inflammatory protein-1 beta precursor, macrophage inflammatory protein-2 
alpha, C5a anaphylatoxin receptor,  CDW40 antigen, mast/stem cell growth factor 
receptor precursor (CD117 antigen), granulocyte colony stimulating factor receptor 
precursor, macrophage colony-stimulating factor-1 receptor precursor, glia maturation 
factor beta, neurotrophin-3 precursor, Trk-T3, insulin-like growth factor-binding protein-
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2, neurotrophin-4, colon carcinoma kinase-4 precursor + transmembrane receptor PTK7, 
secreted apoptosis related protein, tumor necrosis factor alpha precursor, tumor necrosis 
factor receptor superfamily member-1A, tumor necrosis factor receptor superfamily 
member-1B, WSL protein + TRAMP + Apo-3 + death domain receptor-3, platelet-
derived growth factor-A subunit precursor, inhibin beta-A subunit precursor, cysteine-
rich fibroblasts growth factor receptor-1, heparin-binding EGF-like growth factor, ErbB3 
proto-oncogene, endothelin-2, SL cytokine precursor, vascular endothelial growth factor 
precursor, vascular endothelial growth factor receptor-3, endothelial-monocyte activating 
polypeptide-2, wingless-related MMTV, frizzled homolog, jagged homolog-1, 
neurogenic locus Notch protein (not the same as the previously discussed neurogenic 
locus Notch protein homolog-1), Manic Fringe homolog precursor, BIGH3, 
corticotropin-releasing factor receptor 1 precursor, basigin precursor, hepatoma-derived 
growth factor, G-protein-coupled receptor HM74,  Oncostatin M, and epithelial discoidin 
domain receptor-1 precursor.   
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Table 5.  Summary of Array Data. 
 
 Array 1 2 3 4 5 6 7 8 9 10 
 Cord Day Day 0  Day 0  Day 0  Day 0 Day 0 Day 14  Day 14 Day 14 Day 14 Day 14 
 Hybridization Date 1/29/01 3/1/01 3/1/01 4/6/01 4/6/01 1/25/01 3/1/01 3/1/01 4/6/01 4/6/01 
 RNA Isolation Date 12/15a 12/15a 12/6/00 12/6/00 12/6/00 12/15a 12/15a 2/14a 2/14a 2/14a 
 Trial Number Trial 1 Trial 2 Trial 1 Trial 2 Trial 3 Trial 1 Trial 2 Trial 1 Trial 2 Trial 3 
Location Gene/Protein Name           
1A Housekeeper Control ++ ++ +++ ++ + + + +   
1B Housekeeper Control  + +     +   
1D Housekeeper Control ++ ++  +++ +++ + +++ +++ ++  
1E Housekeeper Control  +  + + + +++ +++ +  
1F Housekeeper Control    + +   +++   
1G Housekeeper Control + ++  + +  + +++   
1H Housekeeper Control ++ ++  ++ ++ + + +++   
1I Housekeeper Control  +  + +  + +++   
1O Calibration Marker  +  + +   ++   
1P Calibration Marker + +  + +   +++   
2A Orientation Mark  +  + +   +   
2P Orientation Mark  +  + +   ++   
3C Interleukin 1 beta precursor; catabolin     +   +++   
3H Interleukin 6 precursor; B-cell stimulatory factor 2; 
interferon beta 2, hybridoma growth factor 
 +  + + ++ ++ +++ +  
3J Interleukin 8 precursor; monocyte-dervied 
neutrophil chemotactic factor; T-cell chemotactic 
factorl neutrophil-activation protein 1; lymphocyte-
derived neutrophil-activation factor; protein 3-10c; 
granulocyte chemotactic protein 1; emoctakin 
 +++  ++ +++  + +++   
3L Interleukin 10 precursor; cytokine synthesis 
inhibitory factor 
   + +  + +   
4B Interleukin 13 precursor; NC30  +  +  ++ ++ ++   
4F Interleukin 1 receptor antagonist protein precursor  + +++     ++   
4G Interleukin 1 receptor type II precursor; IL1R-
alpha; p80; CDW121A antigen 
 +  +   ++ ++   
4H Interleukin 1 receptor type II precursor; IL1R-beta  +  + ++   +++   
4I Interleukin 2 receptor alpha subunit precursor; TAC 
antigen; CD25 antigen 
 +++  +++ +++ ++ +++ +++ +++ ++ 
4J Interleukin 2 receptor beta subunit precursor; p70-
75; CD122 antigen 
       +   
4K Interleukin 2 receptor gamma subunit; cytokine 
receptor common gamma chain precursor 
 +  + +   +++   
4M Interleukin 4 receptor alpha subunit precursor; 
CD124 antigen  
       ++   
4O Interleukin 6 receptor alpha subunit precursor; 
CD126 antigen 
    +   ++   
5B Interleukin 6 receptor beta subunit precursor; 
membrane glycoprotein 130; oncostatin M receptor; 
CDW130 antigen 
 +  +    +   
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Table 5, continued. 
 
5C Interleukin 7 receptor alpha subunit precursor; 
CDW127 antigen  
 +  +    +++   
5D High-affinity interleukin 8 receptor alpha; IL8 
receptor type 1; CDW128 antigen 
 +      +   
5H Interferon alpha/beta receptor beta subunit 
precursor; type I interferon receptor 
       ++   
5L Interferon gamma precursor; immune interferon       + +   
5M Interferon gamma antagonist         ++   
5O Interferon gamma receptor; CDW119 antigen        +   
6B Interferon gamma receptor beta subunit precursor; 
IFN-gamma accessory factor 1; IFN-gamma 
transducer 1 
 +  + +   ++   
6C Cytokine humig; interferon gamma-induced 
monokine 
  ++        
6E Interferon regulatory factor 1  +  + +   +++   
6F Leukocyte Interferon Inducible Peptide  +++  +++ +++ +++ +++ +++ +++ + 
6G B cell growth factor 1 precursor; 12-kDa BCGF  +  +++ + + +++ +++ ++  
6H Migration inhibitory factor-related protein 8; 
calgranulin A; leukocyte L1 complex light chain; 
S100 calcium-binding protein A8; cystic fibrosis 
antigen 
 +++  +++ +++  + +++ +  
6I Calgranulin B; migration inhibitory factor-related 
protein 14; leukocyte L1 complex heavy chain; 
S100 calcium-binding protein A9 
+++ +++  +++ +++  + +++ +  
6L Hepatocyte growth factor-like protein; 
macrophage-stimulating protein 
      ++ +   
6M Macrophage-specific colony-stimulating factor        +   
6N Macrophage inflammatory protein 1 alpha 
precursor; tonsillar lymphocyte LD78 alpha 
protein; GOS19-1 protein; PAT 464.2; SIS-beta; 
small inducible cytokine A3 
       ++   
6O Macrophage inflammatory protein 1 beta precursor; 
T-cell activation protein 2; PAT 744; H400; SIS-
gamma; lymphocyte activation gene 1 protein; 
HC21; small inducible cytokine A4; G 26 T-
lymphocyte secreted protein 
       +   
7B Macrophage inflammatory protein 2 alpha; growth-
regulated protein beta 
 +  + +   +++   
7C Macrophage migration inhibitory factor; 
glycosylation-inhibiting factor 
  ++        
7E Small inducible cytokine subfamily B5; epithelial-
derived neutrophil-activating peptide 78 
 +  + ++   +++   
7F Small inducible cytokine A5, regulated on 
activation normal T-cell expressed and secreted 
protein precursor 
+ +++  +++ ++ +++ +++ +++ +++ + 
7K C5a anaphylatoxin receptor; CD88 antigen        +   
7N CDW40 antigen; CD40L receptor precursor; nerve 
growth factor receptor-related B-lymphocyte 
activation molecule 
       +   
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Table 5, continued. 
 
7O c-kit proto-oncogene; mast/stem cell growth factor 
receptor precursor; CD117 antigen 
      + +   
8D Granulocyte colony stimulating factor receptor 
precursor; CD114 antigen 
+ ++  + + +  +++   
8E Granulocyte-macrophage colony-stimulating factor 
receptor alpha; CSW116 antigen 
   +   + + +  
8G Macrophage colony-stimulating factor I receptor 
precursor; c-fms proto-oncogene; CD115 antigen 
       +++   
8O Glia maturation factor beta        +   
9D Neurotrophin 3 precursor; nerve growth factor 2      +     
9O Trk-T3; P68 TRK-T3 oncoprotein        +   
10C Ephrin type A receptor 1 precursor    +    +   
10D Tyrosine-protein kinase receptor tyro3 precursor; 
rse; sky; dtk 
     +     
10F Eph-related receptor tyrosine kinase ligand 1 
precursor; LERK-1; immediate early response 
protein B61; tumor necrosis factor-alpha-induced 
protein 4 
 +         
11F Colon carcinoma kinase 4 precursor + 
transmembrane receptor PTK7 
     + +++ + ++  
11I Neurotrophin 4; NT5; NT6-alpha; NT6-beta; NT6-
gamma 
      ++ + ++  
11N Insulin-like growth factor-binding protein 2       + +   
12E Insulin Receptor precursor  +  +  + + + ++  
12F Insulin-like growth factor I receptor        +   
12J CD30 ligand; CD 153 antigen        +   
13A Orientation Mark  +  + +   ++   
13P Orientation Mark  +      ++   
14E Lymphotoxin-beta; tumor necrosis factor C  +      ++   
14G Secreted apoptosis related protein  +  +  + +++ + +++  
14I Tumor necrosis factor alpha precursor; cachectin  +   +   +++   
14J Tumor necrosis factor receptor superfamily member 
1A; tumor necrosis factor receptor 1; tumor 
necrosis factor-binding protein 1; CD120A antigen 
      + +   
14K Tumor necrosis factor receptor superfamily member 
1B; tumor necrosis factor receptor 2 precursor; 
tumor necrosis factor-binding protein 2; CD120B 
antigen 
 +  + +  ++ +++   
14M WSL protein + TRAMP + Apo-3 + death domain 
receptor 3 
     + ++ ++ +  
14N Platelet-derived growth factor A subunit precursor  +  + +  + +++   
15F Transforming growth factor beta  ++  + + + ++ +++ +  
15G Transforming growth factor beta2 precursor; 
glioblastoma-derived T-cell suppressor factor; bsc-
1 cell growth inhibitor; polyergin; cetermin 
 +    + + + +  
15J Bone morphogenetic protein 2A  +     + ++   
15M Bone morphogenetic protein 4; BMP2B        + +   
16F Inhibin beta A subunit precursor; activin AB alpha 
polypeptide 
     +++ +    
17G Cysteine-rich fibroblasts growth factor Receptor 1; 
Golgi membrane sialoglycoprotein MG160; GLG1 
 +    +++ ++ ++ ++  
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Table 5, continued. 
 
17M Heparin-binding EGF-like growth factor; diphtheria 
toxin receptor 
       ++   
18B Teratocarcinoma-derived growth factor 1; 
epidermal growth factor-like CRIPTO protein 1; 
CR3; CRIPTO-1 growth factor; teratocarcinoma 
derived growth factor 
 +  ++ + + ++ +++ +  
18G WebB2 receptor protein-tyrosine kinase; neu proto-
oncogene; c-erbB2; HER2 receptor 
      +    
18H ErbB3 proto-oncogene; HER3       + +   
18L Endothelin 2  +    + ++ +++  + 
19B Ribonuclease/angiogenin inhibitor; placental 
ribonuclease inhibitor 
       +   
19C SL cytokine precursor; FMS-related tyrosine kinase 
3 ligand 
 +  +  +++ + +++ + 
19F Vascular endothelial growth factor precursor; 
vascular permeability factor 
       +   
19L Vascular endothelial growth factor receptor 3 
precursor; FMS-related tyrosine kinase 4 
       +   
19D Vascular endothelial growth factor B precursor and 
VEGF-related factor 186 
     +     
20B Endothelial-monocyte activating polypeptide 2      +  +   
20F Smoothened homolog   +   ++ + + +  
20H Wingless-related MMTV Integration Site 5a 
Protein 
 ++  ++ + +++ +++ +++ +++ + 
20L Frizzled homolog      + +  +  
21D Jagged homolog 1      + +  +  
21E Jagged homolog 2    ++  +     
21F Neurogenic locus Notch protein  +      ++   
21G Neurogenic locus Notch protein homolog 1 
precursor; translocation-associated Notch protein 
 +      +   
21K Manic Fringe homolog precursor        +   
22B BIGH3  +      +++   
22C Calcitonin receptor   +        
22E Corticotropin-releasing factor receptor 1 precursor, 
corticotropin-releasing hormone receptor 1 
 ++   + +++ +++ +++ +++ + 
22F Basigin precursor; leukocyte activation anitgen M6; 
collagenase stimulatory factor; ECM 
metalloproteinase inducer; 5F7; CD147 Antigen 
     +++  +   
22K Hepatoma-derived growth factor        +   
22L G-protein-coupled receptor HM74        +   
22M CXC chemokine receptor type 4; stromal cell-
derived factor 1 receptor; fusin; leukocyte-derived 
seven transmembrane domain receptor; LCR1 
++ ++      +++   
23B Oncostatin M        +   
23C Platelet-activating factor receptor  +      +   
23F Renin-binding protein   ++        
23G Thrombin Receptor; F2R; PAR1      +     
23H Thymosin beta 10; PTMB10 ++ +++  + + + ++ +++ ++ ++ 
23J Epithelial discoidin domain receptor 1 precursor; 
cell adhesion kinase; TRKE; RTK6; protein 
tyrosine kinase 3A; neuroepithelial tyrosine kinase 
     + +  +  
24A Orientation Mark  +      +   
24P Orientation Mark  +      ++   
+++ 
 
List of the all spots seen on all array membranes.  Key: +++ indicates strong signals (dark dots on 
membrane); ++ indicates moderate signals (medium dots); + indicates low signals (light dots). 
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RT-PCR 
 
 Four main candidates were chosen from the hybridization array results for further 
analysis by RT-PCR.  All four candidates were seen as potentially upregulated in day-14 
cell on the arrays and were chosen because of their known roles in stem cell function.    
Figure 21 shows the RT-PCR results using primers for CD117.  
 
 
 
Figure 21.  RT-PCR Results for Candidate CD117. 
 
 
As seen in the figure CD117, stem cell growth factor receptor, was upregulated in day-14 
vs. day-0 cells in five independent RT-PCR experiments and one repeat experiments.  
The first trial (N=1a and N=1b) shows intra-sample results.   
 Notch-2, a receptor involved in the Notch signaling pathway, was shown to be 
downregulated (Figure 22) in trials 1, 2 and 3 and upregulated in trial 4 and 5.  The 
downregulation contracts with the upregulation seen in the hybridization arrays.  Again, 
trial one was repeated to test intra-sample results. 
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Figure 22.  RT-PCR Results for Candidate Notch-2. 
 
 
 Jagged-2, a ligand involved in the Notch signaling pathway was seen to be 
upregulated in day-14 vs. day-0 samples in all four RT-PCR trials shown in Figure 23.  
This correlates nicely with the results obtained from the hybridization arrays.  A trial to 
test RT-PCR intra-sample variability for Jagged-2 was not performed due to a lack of 
RNA samples. 
 
 
Figure 23.  RT-PCR Results for Candidate Jagged-2. 
 
 
Lastly, the result from the RT-PCR analysis of Manic Fringe, which is a modifier 
in the Notch signaling pathway, is shown (in Figure 24) to be upregulated in day-14 vs. 
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day-0 in four independent trials, and about equal in expression for one trial.  This 
correlates with the results seen in the hybridization arrays.   
 
 
 
Figure 24.  RT-PCR Results for Candidate Manic Fringe. 
 
 
 
Restriction Mapping 
 
 Restriction mapping was performed on the amplicon for Notch-2 to prove the 
identity of the PCR band amplified (Figure 25). 
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 Figure 25.  Restriction Mapping of Candidate Notch-2. 
In the sequence figure, only a portion of the amplified 
fragment is shown. 
 
 
 
Enzyme HincII produced fragment of the expected size (lane 3), but BpmI unexpectedly 
did not cut.  The success in obtaining fragments of the correct size for Notch-2 cut with 
HincII could be due to the fact that HincII tends to cut DNA easily under many different 
salt conditions.  The other three RT-PCR amplicons also remained uncut by their 
enzymes.  To try to solve this problem, the PCR products were ethanol precipitated and 
dissolved in buffers that correspond to the preferred buffer for a given restriction enzyme, 
but again the bands remained uncut (data not shown).  In the future the amplicons will be 
sequenced for positive identification. 
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Western Blots  
 
Western Blots were used to determine whether CD117 protein increased at day-14 
like its mRNA.  The antibody for CD117 was commercially available and purchased 
from BD PharMingen (catalog number 555714).  Figure 26 displays a Western blot 
performed on cell lysates from a full time course of amplification.   
 
Figure 26. CD117 Western blot. 
 
A biotinylated marker was not available when performing this time course.   The sizes on 
the gel were predicted by comparison to a kaleidoscope marker.  From those results, an 
approximate size for the upper band seen in the day-14 sample is 65 kDa and 20 kDa for 
the lower band.  This does not correlate with the published molecular weight of CD117, 
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which is 145 kDa (Elmore et al., 2001), but the bands were repeatedly seen so perhaps 
they represent a CD117-related protein or a denatured fragment.   
 If this band represents CD117, the data are contradictory to what would be 
expected.  The highest number of HSCs in ViaCell’s cellular product is at post-sep-2, not 
at day-14 so the post-sep-2 sample should have shown the strongest CD117 band.  This 
would suggest that the upregulation of CD117 is not due to the higher number of HSCs in 
the population, but from the growth factors being given to the cells in culture.   Further 
investigation of CD117 with fresh cell lysates and with a molecular weight marker need 
to be done. 
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 DISCUSSION 
 
 
 The purpose of this project was to analyze the differential expression of cytokine 
mRNAs in unamplified UCB cells (containing ~0.3% CD34+/CD38- cells on average) 
versus cells amplified by ViaCell’s Selective Clonogenic Amplification patented 
Technology (containing ~11% CD34+/CD38- cells on average).  This goal was 
accomplished by isolating total cellular RNA from pooled UCB cells obtained from 
ViaCell, synthesizing 32P-labelled cDNA, then hybridizing the cDNA to commercially 
available nylon membranes containing 268 carefully chosen cytokine and cytokine 
receptor synthetic cDNAs.  The resulting membranes were exposed to film and the 
expression patterns were identified.   
 
RNA Isolations 
Regarding the RNA isolations, our data indicate that the Clontech procedure for 
isolating total cellular RNA from blood works well for HCB samples when >107 CD45+ 
cells were used.  Yields varying from 0.4 µg to 322 µg were routinely obtained, and 
denaturing agarose electrophoretic analyses displayed sharp, discrete 28S and 18S 
rRNAs indicating intact RNA.  Yields were usually sufficient for multiple analyses (both 
arrays and RT-PCR).  However, yields were highly variable, perhaps due to cord 
differences or technique.  A microscale procedure, using glycogen as a carrier applied to 
106 CD45+ cells, usually provided 0 µg-160 µg RNA, however this yield was usually not 
sufficient for repeated analyses. 
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Hybridization Arrays 
The hybridization array approach used in this project had the advantage of being 
able to simultaneously screen 268 carefully chosen cytokine mRNAs, but this approach 
also had some disadvantages.  One disadvantage is that using Clontech’s recommended 
RNA isolation protocol, so many cells were required (>107) that cords were pooled 
(usually 3) to obtain enough material.  When we used less than this, no RNA pellet was 
obtained.  This meant we were unable to assay individual cords, which might have shown 
interesting cytokine differences between individual donors. Secondly, the Clontech 
procedure did not produce RNA clean enough to survive 37°C incubations with DNase.  
In the future, different RNA isolation procedures could be tried to lower the required 
starting material to one cord (after all, only 1 µg total RNA is needed per cDNA 
reaction), and to produce cord RNA samples clean enough (free of RNases) to allow 
37°C DNase treatments.  Lastly, the hybridization arrays can only be used a maximum of 
three times.   Therefore new arrays must be purchased after the maximum of three uses.   
Regarding the arrays, in our hands the variable having the greatest impact on dot 
profiles was the specific activity of the probes.  Within a given RNA sample, the number 
of dots displayed varied from experiment to experiment.  Nevertheless, when high 
specific activity probes were used, all housekeepers were usually present, and the main 
expression profiles were mostly reproducible for a given sample.  Our most accurate 
comparisons were achieved under conditions in which the housekeepers were equally 
visible. 
The variability and reproducibility of these hybridization array methods were 
addressed in several ways.  Inter-sample variability was tested by performing the same 
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array protocol on different day-0 samples or day-14 samples.  Although some differences 
were observed, the main expression patterns were mostly reproducible.  Stripping the 
original membrane and reusing it with a new batch of cDNA prepared from the same 
RNA tested intra-sample variability, the variability seen using one specific sample.  
These assays showed the greatest consistency, however in our hands, a given membrane 
could only be used a total of 3 times.  In the future we also need to test inter-filter 
variation more accurately by using one large cDNA reaction split in half.  Because 
differences in the specific activity of individual 32P-cDNA samples varied so much, 
(which greatly affected the total number of dots displayed) future attempts will be made 
to assay probe specific activity before proceeding with the experiment, or to analyze only 
those arrays hybridized to high specific activity probes. 
Several candidate mRNAs appeared to be expressed equally between the day-0 
and day-14 samples.  These candidates included: several interleukins (IL-8, IL-10), 
interleukin receptors (IL-2R, IL-6R), growth factors (B-cell growth factor, leukocyte IFN 
inducible protein, small inducible cytokines A5 and B5, TGF-β), inhibitory factors 
(migration inhibitory factor), developmental homologs (smoothened homolog), and 
others (platelet-activating-R, thymosin-β, insulin-R, and calgranulin-B).   
For the day-14 samples, however, many more types of mRNAs were repeatedly 
observed, including:  several interleukins (IL-1β, IL-6, IL-13), interleukin receptors (IL-
1R, IL-2R, IL-7R), growth factors (hepatocyte growth factor-like protein, platelet-
derived growth factor, MCSF, small inducible cytokines A3 and A4, inhibin-β, glial 
maturation factor, NGF-2, Trk-T3 oncoprotein, PTK-7 colon carcinoma kinase, 
neurotrophin-4, insulin-like growth factor-binding protein, oncostatin-M, EGF-like 
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growth factor, hepatoma-derived growth factor, ErbB3 proto-oncogene, endothelin-2, SL 
cytokine, vascular endothelial growth factor, endothelial monocyte activating 
polypeptide), growth factor receptors (FGF-R, CD88, CDW40, CD117 stem cell growth 
factor-R, CD114 GCSF-R, CD115 MCSF-R, epithelial discoidin-R, G-protein-coupled-
R, CRF-R, vascular endothelial-R), developmentally interesting proteins (Manic Fringe 
homolog, wingless, frizzled, jagged-1, Notch protein), interferon-related proteins (IFN-α-
R, IFN-β-R, IFN-γ antagonist, IFN regulatory factor), and other proteins (BIGH3, humig, 
basigin).  
This is exciting information since the observed upregulations did not contain 
many inflammatory cytokines, which could hinder survival of these therapeutic cells as 
grafts in the future.  Only small upregulations of macrophage inflammatory protein-1 α 
and β, TNF-α, and TNF-R were observed.   
           
Further Analysis of Selected Candidates by RT-PCR 
Several developmentally interesting mRNA candidates were upregulated in the 
day-14 samples.  Jagged-1 was detected in three day-14 experiments, but in none of the 
five day-0 experiments.  Jagged-1 represents a growth factor of human stem cells, and is 
expressed by uncommitted human hematopoietic cells and cells that comprise the 
putative blood stem cell microenvironment (Karanu et al., 2000).  Another 
developmentally interesting cytokine expressed in day-14 cells was the Frizzled 
Homolog.  It was detected in three of the day-14 experiments, but in none of the five day-
0 experiments.  Frizzled is a protein, which can stimulate the survival and proliferation of 
hematopoietic progenitors (Austin et al., 1997).    However these two interesting 
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candidates were not pursued further because initial attempts at RT-PCR failed to produce 
amplicons of the corrected size, so perhaps in the future different primer sets could be 
tested. 
 Four other candidates identified using the hybridization arrays were chosen for 
further analysis by RT-PCR.  These candidates include CD117 (c-kit), Jagged-2, Manic 
Fringe, and Notch.   
   
CD117   
CD117 is a stem cell growth factor receptor.  Using RT-PCR CD117 was shown 
to be upregulated in day-14 cells relative to day-0 in five independent trials.  The 
upregulation of CD117 is exciting because it validates ViaCell’s clonogenic 
amplification protocol for this stem cell-enriched fraction. 
Stem Cell Growth Factor receptor (c-kit, CD117) is expressed on almost all 
hematopoietic progenitor cells, and the receptor/ligand interaction is crucial for the 
development of hematopoietic stem cells.  CD117 is a tyrosine kinase cell surface 
receptor for stem cell factor (Carson et al., 1994) known to support the cycling of CD34+ 
cells in the absence of other cytokines (Birkmann et al., 1997).   
Since many contradictory reports have been published on the expression of 
CD117 in conjunction with HSCs, a study was done by Ratajczak et al. (1999) to 
reevaluate the role of CD117.  They validated CD117’s status as a stem cell marker by 
finding that human HSCs do not reside within a CD34+KIT- cell population.  Cells 
isolated from human bone marrow were sorted by FACS and evaluated for their ability to 
engraft in an immunodeficient SCID mouse model.  Only CD34+KIT+ cells, but not 
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CD34+KIT- or CD34-KIT- cells, possess the ability to establish a human-murine 
hematopoietic chimerism in the mice.  They argue that CD117 is a very useful marker for 
identifying human HSCs, present in CD34+KIT+ cell populations. 
Many studies have been performed to determine the role that CD117 and its 
ligand have on hematopoietic progenitor cells. A study done by Simmons et al. (1994) 
examined the expression of c-kit protein on primitive CD34+ hematopoietic cells isolated 
from human bone marrow.  They looked for coexpression of c-kit and early lymphoid 
markers in the CD34+ populations by multiparameter flow cytometry, and found 
coexpression of c-kit only on a minority of cells with markers of B or T lineages.  
However, the vast majority of early lymphoid cells lacked c-kit expression.  
 
Notch Signaling Pathway 
The Notch protein is a surface receptor that transmits signals received from 
outside the cell to the cell’s interior.  Its main function is to repress the adoption of 
differentiation by cells that carry the Notch protein  (Society for Developmental Biology, 
2000) as seen in Figure 27.   
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Figure 27.  The role of Notch in differentiation. 
When DSL proteins (the ligands for Notch) bind, an inhibition 
of differentiation is observed.  Differentiation is observed 
when the receptor/ligand interaction does not occur (Milner 
and Bigas, 1999). 
 
 
 Members of the Notch family have a critical role in hematopoiesis by regulating 
cell fate and self-renewal of progenitors (Milner and Bigas, 1999). Table 6 summarizes 
the components involved in the Notch-signaling pathway in flies, worms, and mammals. 
 
 
 
 
 
 
 
 
 69 
 C. elegans Drosophila Mammals 
NOTCH receptors Lin-12 Glp-1 Notch 
Notch-1, Notch-2, 
Notch-3, Notch-4 
Extracellular ligands 
(DSL proteins) 
Lag-2 
Apx-1 
Delta 
Serrate 
Delta-1, Delta-like-1, 
Delta-like-3 
Jagged-1 (Serrate-1), 
Jagged-2 (Serrate-2) 
Intracellular effectors Lag-1 Suppressor of Hairless Deltex 
CBF-1/RBP-JK 
Deltex NFKB 
Target genes  
Enhancer of split 
bHLH 
Groucho 
HES (Hairy/Enhancer of 
split) 
bHLH 
TLE 
Processing molecules SUP-17 Kuzbanian Kuzbanian 
Modifiers  
Fringe 
Numb 
Dishevelled 
Lunatic Fringe, Manic 
Fringe, Radical Fringe 
Numb,Numb-like 
Dishevelled 1,2,3 
 
Table 6. Components of the Notch Signaling Pathway. 
(Milner and Bigas, 1999) 
 
 Notch signaling can occur either among a group of equivalent cells (homotypic 
interactions) or between nonequivalent cells (heterotypic interactions) (Milner and Bigas, 
1999).  In homotypic interactions, a group of equipotent cells exposed to a specific 
differentiation signal will adopt a specific cell fate, whereas adjacent cells (that express 
more Notch) are inhibited from differentiating (Milner and Bigas, 1999).  The 
uncommitted cells may undergo alternative fates, which again is regulated by Notch.  
Heterotypic interactions are regulated by the binding of Notch with its ligands DSL 
proteins, making Notch activation dependent on those cells that are in direct contact with 
ligand-expressing cells and by other molecules such as Fringe and Wingless (Milner and 
Bigas, 1999).  The overall regulation of Notch is viewed as inhibiting differentiation of 
cells along a specific pathway, leaving undifferentiated cells capable of expanding or 
adopting a default pathway.  In the context of the normal hematopoietic 
 70 
microenvironment, regulation of Notch activity through extracellular ligand binding will 
permit only those cells maintaining the highest relative levels of Notch expression to 
remain multipotent (Milner et al., 1996).  Other factors activate or inactivate the Notch 
pathway.  When Granulocyte Colony Stimulating Factor (G-CSF) is introduced, it 
activates Notch through its effects on the Notch-1 receptor (Bigas et al., 1998).  In the 
same way, when Granulocyte Macrophage Stimulating Factor (GM-CSF) is introduced, it 
activates Notch through its effects on the Notch-2 receptor (Bigas et al., 1998).  Better 
understanding of the conditions of activation and inactivation of the Notch signaling 
pathway may help in further studies of stem cell expansion techniques. 
 
Notch-2 
 Although Notch-2 mRNA appeared to be increased in day-14 populations relative 
to day-0 by array analyses, in agreement with its role in preventing differentiation, it 
actually was down regulated according to three RT-PCR trials.  Notch 2 is one of the four 
known Notch receptors.  Notch receptors are present on the surface of the cell as 
heterodimers, generated by cleavage of full-length Notch protein and reassociaton by 
disulfide bonds of extracellular and intracellular cleavage products (Milner and Bigas, 
1999).  It has been shown that the Notch-2 receptor (as well as Notch 3 and 4) is 
expressed by human hematopoietic progenitors (Milner et al., 1994).  A detailed 
investigation of the Notch receptors by Milner and colleagues showed: 
the ability of two mammalian Notch homologs, mouse Notch1 and 
Notch2, to inhibit the granulocytic differentiation of 32D myeloid 
progenitor cells. 32D cells undergo granulocytic differentiation when 
stimulated with either granulocyte colony-stimulating factor (G-CSF) or 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Expression 
of the activated intracellular domain of Notch1 inhibits the differentiation 
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induced by G-CSF but not by GM-CSF; conversely, the corresponding 
domain of Notch2 inhibits differentiation in response to GM-CSF but not 
to G-CSF. The region immediately C-terminal to the cdc10 domain of 
Notch confers cytokine specificity on the cdc10 domain. The cytokine 
response patterns of Notch1 and Notch2 are transferred with this region, 
which we have termed the Notch cytokine response (NCR) region. The 
NCR region is also associated with differences in posttranslational 
modification and subcellular localization of the different Notch molecules. 
These findings suggest that the multiple forms of Notch found in 
mammals have structural differences that allow their function to be 
modulated by specific differentiation signals (Bigas et al., 1998). 
 
The effects of Notch1 and Notch2 may vary among individual cells.  The signaling of 
Notch receptors with its ligands could prove to be a mechanism in which progenitor cells 
“communicate” with each other to signal differentiation of cells while also inhibiting 
differentiation of other cell types in order to keep a pool of mulitpotent progenitors.  The 
apparent disconnect between our array and RT-PCR data for Notch-2 warrants further 
investigation. 
 
Manic Fringe 
Manic Fringe homolog was upregulated in three independent RT-PCR trials.  
Manic Fringe homolog, one of three mammalian homologs of Drosophila Fringe (Manic, 
Lunatic, and Radical), modulates the activation of the Notch signal transduction pathway.  
Expression studies in mouse embryos support a conserved role for mammalian Fringe 
family members in participation in the Notch signaling pathway leading to boundary 
determination during segmentation (http://stemcell.princeton.edu/table1.html).  Manic  
Fringe, specifically, was found to be highly expressed in uncommitted precursor cells as 
well as in committed neutrophil and macrophage precursors by Singh and colleagues 
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(2000).  Thus our RT-PCR and array data for Manic Fringe further validates the ViaCell 
purification protocol.  
 The Fringe genes encode molecules that modulate interactions between Notch and 
ligands (Milner and Bigas, 1999).  The Fringe protein modulates the ability of Notch 
ligands to activate Notch signaling (Moloney et al., 2000).  The molecular mechanism in 
which this happens has not been determined. Recent work by Moloney et al. (Ibid.) 
proposes that Fringe modulates Notch signaling by direct modification of O-linked 
fucose residues within EGF repeats of the Notch extracellular domain.  These results are 
inconsistent with the recent proposal that Fringe functions by forming a stable complex 
with Notch (Ju, 2000). Even though the mechanism in which Fringe influences Notch is 
unknown, it is certain that it has a role in affecting the differentiation of cells through the 
Notch-signaling pathway. 
Manic Fringe is a modifier of the Notch-signaling pathway.  Its effect on 
differentiation is seen in Figure 28.  Manic Fringe must be expressed on the same cell as 
Notch in order to have an effect on the Notch-signaling pathway.  Manic Fringe 
potentiates signaling from Delta while inhibiting signaling from Jagged (Haltiwanger, 
2001). 
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 Figure 28.  The Effect of Manic Fringe on the Notch-Signaling Pathway. 
   
Jagged-2 
Jagged-2 was seen to be upregulated in day-14 cells in four independent RT-PCR 
experiments.  A higher expression of Jagged-2 could mean that the amplified stem cells 
are in fact uncommitted HSCs because it is known that Jagged-2 is expressed by 
uncommitted HSCs that comprise the putative blood stem cell microenvironment 
(Karanu et al., 2000).  This upregulation could be used as a marker for HSCs in future 
cell lines to be used for human grafting. 
Jagged-2 is an extracellular ligand involved in the Notch-signaling pathway. 
Coexpression of Jagged-2 and Notch-1 in the developing thymus suggests that Jagged-2 
is a ligand for the Notch-1 receptor (Milner and Bigas 1999). Work by Luo et al. (1997) 
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found that a culture of fibroblasts expressing human Jagged-2 in murine C2C12 
myoblasts inhibited myogenic differentiation accompanied by increased Notch-1.  The 
exposure of C2C12 cells to Jagged-2 led to increased amounts of Notch mRNA.  The 
binding of Jagged-2 to Notch-1 caused a positive feedback control of genes seen when 
active forms of Notch-1 induced increased levels of the same set of mRNAs.   This 
feedback control may function in vivo to coordinate the differentiation of progenitor cells 
adopting identical cell fates (Luo et al., 1997).  Work done by Singh et al. (2000) found 
that activation of endogenous Notch by Jagged-2 decreased proliferation and reduced 
differentiation of normal human CD34+ cells.  
          Studies presently being done to examine the role of the Notch-signaling pathway 
on differentiation suggest that Notch ligands, such as Jagged-2, may be useful for in vitro 
expansion of hematopoietic stem/progenitor cells.  However, the complex interactions 
involving various Notch molecules, ligands, and cytokines may present a considerable 
challenge (Milner and Bigas, 1999).    A brief summary of the effects of the expression of 
Notch receptors (such as Notch-2) and ligands (such as Jagged-2) on differentiation of 
cells is seen in Figure 29. 
 If its true that Manic Fringe blocks the interaction of Jagged-2 with Notch 
receptor (Haltiwanger, 2001) it is not immediately clear how to explain our observed 
increases in both Manic Fringe and Jagged-2.  Perhaps the subset of cells showing the 
increase in Manic Fringe act to facilitate Notch signaling via Delta proteins (blocking cell 
differentiation), while a different subset of cells express Jagged-2 to also stimulate Notch 
signaling. 
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Figure 29.  The Effects of the Expression of Notch Receptors and Ligands on Differentiation. 
           
 
 
Future Experiments 
 
      In the future, the array work could be expanded to include post-sep-2 samples 
which are especially enriched (~33% of the cell population) for CD34+/CD38-/Lin- stem 
cells.  Only high specific activity probes should be used.  For the RT-PCR experiments, 
those candidates showing a disconnect with the arrays could be further investigated by 
designing different primers for that mRNA to ensure the correct mRNA is being 
analyzed.  The Western blots need to be improved by running markers on all gels, and by 
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extending the analysis to candidates other than CD117 if appropriate antibodies are 
available. 
Regarding new potential treatments of the cultured stem cells, more work could 
be done to try to activate the Notch-signaling pathway (i.e. by adding Jagged-2 to the 
medium).  This activation could be very beneficial since it inhibits the differentiation of 
cells and could minimize production of unwanted mature cells in grafts.  This activation 
allows for in vitro expansion of a culture of HSCs, since the cells are inhibited from 
further differentiation.  To test for specific Notch pathway activation a microarray, 
similar to the one used for this project, could be custom designed that contains all of the 
components of the Notch signaling pathway.  In order to better design an optimal array 
for ViaCell, preliminary experiments could be done by testing the expression of genes on 
an array other than one specific for human cytokines and their receptors.  The 
developmentally interesting non-cytokine related candidates could be added to the 
custom designed array. The results of this array would give a better understanding of the 
mechanisms affecting differentiation of the cell samples obtained from ViaCell.   
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